<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialRecordsOutput><serviceExecutionTime>276</serviceExecutionTime><Trial id="164456"><TitleDisplay>To Assess the Level of Adherence of Subjects Receiving SAIZEN Via Easypod in Middle East</TitleDisplay><TitleOfficial>Easypod Connect: A Regional, Multicenter, Observational Study to Evaluate Adherence and Long-Term Outcomes of Therapy in Pediatric Subjects Using Easypod Electromechanical Device for Growth Hormone Treatment</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02015286</Identifier><Identifier type="Organisational Study">EMR 200104-534</Identifier><Identifier type="Trial Acronym">ECOS UAE</Identifier></Identifiers><Indications><Indication id="2535">Growth hormone deficiency</Indication></Indications><BiomarkerNames><BiomarkerName id="379" role="Therapeutic effect marker" type="Genomic;Proteomic">Insulin-like growth factor 1</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>easypod</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>somatropin, Serono</Name><Drug id="10019">somatropin, Serono</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="10019">somatropin, Serono</Drug><IndicationsPioneer/><Companies><Company><Company id="1091317">Merck Serono Middle East FZ LLC</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="18101">Merck KGaA</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="10019" type="Drug"><TargetEntity id="277194" type="siDrug">Somatropin (rmc)</TargetEntity></SourceEntity><SourceEntity id="1091317" type="Company"><TargetEntity id="5037036190" type="organizationId">Merck Serono Middle East FZ LLC</TargetEntity></SourceEntity><SourceEntity id="18101" type="Company"><TargetEntity id="4295869098" type="organizationId">Merck KGaA</TargetEntity></SourceEntity><SourceEntity id="2535" type="ciIndication"><TargetEntity id="10056438" type="MEDDRA"/><TargetEntity id="D004393" type="MeSH"/><TargetEntity id="516" type="siCondition"/><TargetEntity id="1820" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="18101">Merck KGaA</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1091317">Merck Serono Middle East FZ LLC</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="21072">Growth hormone ligand</Action><Action id="22165">IGF1 gene modulator</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="750">Freeze drying</Technology><Technology id="85">Protein recombinant</Technology><Technology id="746">Solution</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Longitudinal</Term><Term>Cohort</Term><Term>Prospective</Term><Term>Retrospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>7</PatientCountEnrollment><DateStart>2014-03-31T00:00:00Z</DateStart><DateEnd type="actual">2015-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-06-27T11:03:29Z</DateChangeLast><DateAdded>2013-12-23T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Merck Serono Middle East FZ LLC</Affiliation><Name>Medical Responsible</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Administered growth hormone via the easypod electromechanical device according to Summary of Product Characteristic (SmPC)&lt;/li&gt;&lt;li&gt;Over the age of 2 years&lt;/li&gt;&lt;li&gt;Under 18 years of age, or over 18 without fusion of growth plates&lt;/li&gt;&lt;li&gt;Parents or guardians written informed consent, given before entering data into the observational study, with the understanding that the subject or parent/guardian may withdraw consent at any time without prejudice to future medical care. If the child is old enough to read and write, a separate assent form will be given as defined in the appropriate jurisdiction of each country&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects taking growth hormone in whom growth plates have fused (that is, for taking growth hormone for it's metabolic effects)&lt;/li&gt;&lt;li&gt;Contraindications to&lt;ulink linkType="Drug" linkID="10019"&gt;Saizen&lt;/ulink&gt; as defined in the SmPC&lt;/li&gt;&lt;li&gt;Use of an investigational drug or participation in another interventional clinical study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Mean percent of daily recorded adherence</Description><Timeframe>At least 6 months and up to five years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Correlation of adherence and growth outcome after each year of SAIZEN treatment with easypod: correlation of adherence and growth outcome (change in: height velocity [HV], height velocity-standard deviation score [HV-SDS], height, height-standard deviation score [height SDS]) after each year of SAIZEN treatment with easypod</Description><Timeframe>At least 6 months and up to five years</Timeframe></Measure><Measure><Description>Correlation of adherence with current IGF-1 status (that is, above, below or within normal ranges)</Description><Timeframe>At least 6 months and up to five years</Timeframe></Measure><Measure><Description>Subject adherence profile based on age, gender, indication, self-injection or not, time on treatment</Description><Timeframe>At least 6 months and up to five years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this middle east, multicenter, observational study was to evaluate adherence and long term      outcomes of therapy in pediatric subjects using easypod electromechanical device for growth      hormone treatment and to assess the level of adherence of subject receiving &lt;ulink linkType="Drug" linkID="10019"&gt;Saizen&lt;/ulink&gt; via      easypod. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would be enrolled in a multicenter, longitudinal, observational study.      Subjects would  receive &lt;ulink linkType="Drug" linkID="10019"&gt;Saizen&lt;/ulink&gt;  via easypod. Adherence data would be      primarily derived from the easypod device combined with physician data entry of outcome      measures. Data would be collected both retrospectively and prospectively. Collected data would be      also analyzed in a multinational pooled analysis of comparable national studies.&lt;/para&gt;&lt;para&gt;The primary objectives was:&lt;br/&gt;To assess the level of adherence of subjects receiving &lt;ulink linkType="Drug" linkID="10019"&gt;Saizen&lt;/ulink&gt; via easypod.&lt;/para&gt;&lt;para&gt;Secondary objectives were:&lt;br/&gt;To describe the impact of adherence on clinical outcomes for subject receiving &lt;ulink linkType="Drug" linkID="10019"&gt;Saizen&lt;/ulink&gt;           via easypod.&lt;br/&gt;To identify adherence subject profiling.&lt;br/&gt;To assess the impact of adherence on Insulin-like Growth Factor 1 (IGF1).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Germany"><Sites><Site><Name>For Recruiting Locations in the United Arab Emirates and the Kingdom of Saudi Arabia</Name><Address1>Please Contact The Merck KGaA Communication Center</Address1><Address2>Darmstadt</Address2><CountrySubDivision>Darmstadt</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02015286</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Actual">2015-12-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2015-03-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>12.03 Months</EnrollmentPeriod><EnrollmentRate>0.58 Patients/Month</EnrollmentRate><DateFirstReceived>2013-12-12T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-12-23T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2014-08-05T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2015-04-29T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2016-05-23T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="173919"><TitleDisplay>Comparative Effectiveness of Prolotherapy Regenerative Injection Technique With Conventional Treatment to Treat Recalcitrant Supraspinatus Tendinosis in Human Subjects</TitleDisplay><TitleOfficial>Comparative effectiveness of prolotherapy regenerative injection technique with conventional treatment to treat recalcitrant supraspinatus tendinosis in human subjects: a randomized, controlled trial</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="ISRCTN">ISRCTN43520960</Identifier><Identifier type="Secondary Organisational">P1055/2010B</Identifier><Identifier type="Other">805.11</Identifier></Identifiers><Indications><Indication id="20">Pain</Indication><Indication id="2935">Tendon disease</Indication></Indications><BiomarkerNames><BiomarkerName id="34644" role="Therapeutic effect marker" type="Structural (imaging)">Tendons</BiomarkerName><BiomarkerName id="46234" role="Therapeutic effect marker" type="Physiological">Shoulder motion</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Prolotherapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>dextrose</Name></Intervention><Intervention type="InterventionPrimary"><Name>lignocaine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>conventional treatment</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="25694" type="Company"><TargetEntity id="5001205299" type="organizationId">University of Malaya</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"/><TargetEntity id="D010146" type="MeSH"/><TargetEntity id="-1585850437" type="omicsDisease"/><TargetEntity id="1" type="siCondition"/></SourceEntity><SourceEntity id="2935" type="ciIndication"><TargetEntity id="10043239" type="MEDDRA"/><TargetEntity id="D052256" type="MeSH"/><TargetEntity id="-1496107283" type="omicsDisease"/><TargetEntity id="2160" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="25694">University of Malaya</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Medical procedure</Category><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>20</PatientCountEnrollment><DateStart>2010-09-01T00:00:00Z</DateStart><DateEnd type="actual">2012-09-01T00:00:00Z</DateEnd><DateChangeLast>2017-11-11T12:29:50Z</DateChangeLast><DateAdded>2014-02-19T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Univeristy Malaya Medical Center, Biomedical Imaging, Lembah Pantai, Kuala Lumpur, 59100, Malaysia</Affiliation><Email>lishyan@hotmail.com</Email><Name>Li Chng</Name><Phone>+603 79493930</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age 18 to 65 years&lt;/li&gt;&lt;li&gt;Able to understand completely the study procedure&lt;/li&gt;&lt;li&gt;Symptomatic tendinopathy&amp;gt; 6 months&lt;/li&gt;&lt;li&gt;Failure of the following conservative modalities: relative rest, physiotherapy, non-steroidal anti-inflammatory drugs and two corticosteroid injection&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Autoimmune Diseases such as Rheumatoid Arthritis etc&lt;/li&gt;&lt;li&gt;Patients on anticoagulant such as Warfarin, unless written consent is obtained from the attending physician&lt;/li&gt;&lt;li&gt;Congenital or Acquired Platelet Dysfunction abnormality/disorder eg, von Willebrand Disease, Glanzmann Disease etc&lt;/li&gt;&lt;li&gt;Hemoglobin level&amp;lt; 10 g/l and/or Platelet count &amp;lt; 100,000/microl&lt;/li&gt;&lt;li&gt;Diabetes&lt;/li&gt;&lt;li&gt;Corticosteroid injection within the past 6 weeks&lt;/li&gt;&lt;li&gt;Self-reported immuno-compromised status&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Areas and site of hypochoic tendinosis at area of maximal tendinosis on cross section scanning of the painful region (expressed in mm2)</Description></Measure><Measure><Description>The intensity of the area of tendinosis and also the ratio of area of tendinosis with normal tendon area (measured in decibels)</Description></Measure><Measure><Description>Number of focal area of tendinosis</Description></Measure><Measure><Description>Presence or absence of calcification and type of calcification (hard or soft)</Description></Measure><Measure><Description>Presence of tears within the tendon, bursal and articular. Length, site and height of tears are identified in cross section area with most and longest tears noted</Description></Measure><Measure><Description>Presence of periostitis</Description></Measure><Measure><Description>The percentage of Doppler flow within the area of tendinosis measured above: none, less than 50% and more than 50%</Description></Measure><Measure><Description>Presence of subacromial bursitis will also be assessed</Description></Measure><Measure><Description>Dynamic impingement test is also done with distance of between acromion and greater tuberosity at maximal abduction is also measured when impingement is positive</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Disabilities of the Arm, Shoulder and Hand (DASH) Score</Description></Measure><Measure><Description>Physical examination of the range of movement of the shoulder</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim was to compare the effectiveness of prolotherapy regenerative injection technique with conventional treatment to treat recalcitrant supraspinatus tendinosis in human patients.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Two study arms which were the prolotherapy regenerative injection therapy group and the control group. The prolotherapy regenerative injection therapy group would receive ultrasound guided prolotherapy injections which consist of a mixture of dextrose 12% and 0.5% lignocaine into the area of tendinosis and also standardized regime physiotherapy practiced by University Malaya Medical Center (UMMC).&lt;/para&gt;&lt;para&gt;The control group would continue conventional therapy of standardized regime physiotherapy practiced by UMMC physiotherapy and analgesics. Patients from both groups would have ultrasound changes, Disabilities of the Arm, Shoulder and Hand (DASH) score and range of movement recorded at baseline and at 12 weeks.&lt;br/&gt;&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Malaysia"><Sites><Site><Name>University Malaya Medical Center</Name><Contacts/></Site><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8387">Subjects with Chronic Pain</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8413">Subjects with Somatic Pain</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8430">Subjects with Intractable Pain</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="ISRCTN">ISRCTN43520960</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="25988"><Endpoint>Assessment of Underlying Conditions</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25992">Musculoskeletal disease related outcomes</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="26014"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26015">Imaging assessments</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pain" id="25959"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="34784"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="34807">Assessment by DASH scale</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22087"><Criterion>Subjects Based on Duration of Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22090">Subjects with chronic pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22125"><Criterion>Subjects with Somatic Pain</Criterion></Inclusion><Inclusion disease="Pain" id="22189"><Criterion>Conditions Associated with Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22207">Subjects with musculoskeletal disorder/injury associated pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22210"><Criterion>Subjects with History/Scheduled for Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="22212">Subjects with history/scheduled to receive NSAIDs</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22258"><Criterion>Subjects with Intractable Pain</Criterion></Inclusion><Inclusion disease="Pain" id="34061"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="22214">Subjects with history of steroid therapy</SubCriterion><SubCriterion disease="Pain" id="22238">Subjects with history/scheduled to receive physiotherapy</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20104"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Pain" id="20110">Subjects with abnormal/unacceptable hematopoietic/marrow function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Pain" id="20113">Subjects co-morbid with metabolic diseases/disorders</SubCriterion><SubCriterion disease="Pain" id="20122">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20119"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Pain" id="20131"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="20135">Subjects with history/scheduled to receive steroids</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20173"><Criterion>Subjects with History/ Scheduled to Undergo Other Therapy/Procedures</Criterion><SubCriteria><SubCriterion disease="Pain" id="20174">Subjects with history/scheduled to receive other drug therapies</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2012-09-01T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>24.03 Months</EnrollmentPeriod><EnrollmentRate>0.83 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-02-19T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="201537"><TitleDisplay>A European Study on Medical Management Versus TAG Device + Medical Management for Acute Uncomplicated Type B Dissection</TitleDisplay><TitleOfficial>A Randomized European Study Comparing Endoluminal Stent Grafting and Best Medical Therapy (BMT) to BMT Alone in the Treatment of Acute Uncomplicated Type B Aortic Dissection</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00742274</Identifier><Identifier type="Organisational Study">TAG 05-04</Identifier><Identifier type="Trial Acronym">ADSORB</Identifier></Identifiers><Indications><Indication id="1606">Aortic disease</Indication></Indications><BiomarkerNames><BiomarkerName id="2586" role="Disease marker" type="Physiological">Blood pressure</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Gore TAG</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1025721" type="Company"><TargetEntity id="5000717243" type="organizationId">W L Gore &amp; Associates Inc</TargetEntity></SourceEntity><SourceEntity id="1606" type="ciIndication"><TargetEntity id="10058648" type="MEDDRA"/><TargetEntity id="D001018" type="MeSH"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1025721">W L Gore &amp; Associates Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>61</PatientCountEnrollment><DateStart>2008-08-31T00:00:00Z</DateStart><DateEnd type="actual">2013-10-31T00:00:00Z</DateEnd><DateChangeLast>2018-04-07T04:58:22Z</DateChangeLast><DateAdded>2014-07-03T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Kilinkum der Universitat zu Koln</Affiliation><Name>Jan Brunkwall, MD, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Presence of acute uncomplicated type B aortic dissection&lt;/li&gt;&lt;li&gt;Able to tolerate endotracheal intubation and general anesthesia&lt;/li&gt;&lt;li&gt;Maximum transverse diameter of the descending thoracic aorta&amp;lt;/= 55 mm and absence of descending thoracic aortic aneurysm, regardless of etiology&lt;/li&gt;&lt;li&gt;Arterial anatomy is appropriate for stent graft therapy&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;ASA classification =  V&lt;/li&gt;&lt;li&gt;Severe renal insufficiency defined as SVS risk renal status = 3&lt;/li&gt;&lt;li&gt;Severe respiratory insufficiency defined as SVS risk pulmonary status = 3&lt;/li&gt;&lt;li&gt;Presence of connective tissue disease&lt;/li&gt;&lt;li&gt;Active infection or active vasculitides&lt;/li&gt;&lt;li&gt;Positive pregnancy test&lt;/li&gt;&lt;li&gt;Participation in another medical research study within 3 months of study enrollment&lt;/li&gt;&lt;li&gt;Myocardial infarction or cerebrovascular accident within 6 weeks prior to study enrollment&lt;/li&gt;&lt;li&gt;Planned concomitant surgical procedures (other than left subclavian artery transposition or bypass), or major surgery within 30 days of study enrollment&lt;/li&gt;&lt;li&gt;History of drug abuse&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Composite of partial or no false lumen thrombosis, aortic rupture, and aortic dilatation: patients with any of the following met this composite outcome: partial/no false lumen thrombosis; aortic rupture; aortic dilatation; lack of one year imaging (no image, incomplete image missing primary endpoint measurements, unevaluable image)</Description><Timeframe>One year</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was  to compare endoluminal stent grafting with the GORE TAG device      and best medical therapy (BMT) to BMT alone in the treatment of acute uncomplicated type B      aortic dissections.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study would be divided into two arms.&lt;br/&gt;Arm 1: patients would be  treated with  Gore TAG device implant and with best  medical therapy per physician discretion.&lt;br/&gt;Arm 2: patients would be treated with  best medical therapy,   a regimen of antihypertensive medications used to maintain blood pressure below 125/80 mm/Hg throughout the entire follow-up period.Â &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00742274</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Actual">2012-02-29T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2011-01-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>29.03 Months</EnrollmentPeriod><EnrollmentRate>2.10 Patients/Month</EnrollmentRate><DateFirstReceived>2008-08-25T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-07-03T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="262268"><TitleDisplay>Randomized oesophagectomy: minimally invasive or open - comparing different approaches to surgery</TitleDisplay><TitleOfficial>ROMIO: Randomized esophagectomy - Minimally Invasive or Open</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="ISRCTN">ISRCTN10386621</Identifier><Identifier type="Organisational Study">30470</Identifier><Identifier type="Trial Acronym">ROMIO</Identifier></Identifiers><Indications><Indication id="1011">Esophagus tumor</Indication><Indication id="127">Stomach tumor</Indication><Indication id="2399">Adenocarcinoma</Indication><Indication id="307">Squamous cell carcinoma</Indication></Indications><BiomarkerNames><BiomarkerName id="1912" role="Therapeutic effect marker" type="Physiological">Forced Vital Capacity</BiomarkerName><BiomarkerName id="2713" role="Therapeutic effect marker" type="Physiological">Forced expiratory volume</BiomarkerName><BiomarkerName id="23541" role="Therapeutic effect marker" type="Structural (imaging)">Esophagus</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>laparoscopically-assisted esophagectomy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>standard open esophagectomy</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1042032" type="Company"><TargetEntity id="5035525916" type="organizationId">National Institute for Health Research</TargetEntity></SourceEntity><SourceEntity id="1049514" type="Company"><TargetEntity id="5025465410" type="organizationId">University Hospitals Bristol NHS Foundation Trust</TargetEntity></SourceEntity><SourceEntity id="1011" type="ciIndication"><TargetEntity id="C15" type="ICD10"/><TargetEntity id="150" type="ICD9"/><TargetEntity id="10061882" type="MEDDRA"/><TargetEntity id="D004938" type="MeSH"/><TargetEntity id="-1694229607" type="omicsDisease"/><TargetEntity id="598" type="siCondition"/></SourceEntity><SourceEntity id="127" type="ciIndication"><TargetEntity id="C16" type="ICD10"/><TargetEntity id="151" type="ICD9"/><TargetEntity id="10017758" type="MEDDRA"/><TargetEntity id="D013274" type="MeSH"/><TargetEntity id="-2031094615" type="omicsDisease"/><TargetEntity id="646" type="siCondition"/></SourceEntity><SourceEntity id="2399" type="ciIndication"><TargetEntity id="10001141" type="MEDDRA"/><TargetEntity id="D000230" type="MeSH"/><TargetEntity id="-1620546969" type="omicsDisease"/><TargetEntity id="656" type="siCondition"/></SourceEntity><SourceEntity id="307" type="ciIndication"><TargetEntity id="10041823" type="MEDDRA"/><TargetEntity id="D002294" type="MeSH"/><TargetEntity id="-1612557995" type="omicsDisease"/><TargetEntity id="676" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>8</NumberOfSites><CompaniesSponsor><Company id="1049514">University Hospitals Bristol NHS Foundation Trust</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1042032">National Institute for Health Research (NIHR)</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>446</PatientCountEnrollment><DateStart>2015-12-01T00:00:00Z</DateStart><DateEnd type="estimated">2021-05-30T00:00:00Z</DateEnd><DateChangeLast>2018-12-21T05:58:16Z</DateChangeLast><DateAdded>2016-06-04T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Name>Dr Brierley</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age &gt;/= 18 years&lt;/li&gt;&lt;li&gt;Referred for primary esophagectomy by the multi-disciplinary team (MDT) or oesophagectomy following re-staging after neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy (NB, in this any type of neoadjuvant treatment may be used)&lt;/li&gt;&lt;li&gt;Confirmed MDT evidence of at least adenocarcinoma or at least squamous cell cancer of the esophagus or oesophago-gastric junction&lt;/li&gt;&lt;li&gt;Fit for pre-operative anaesthesia and surgery, assessed by the MDT&lt;/li&gt;&lt;li&gt;Able to provide written informed consent&lt;/li&gt;&lt;li&gt;Measurement (endoscopic or otherwise) that the tumour starts &gt; 5 cm below crico-pharyngeus&lt;/li&gt;&lt;li&gt;Measurement (endoscopic or otherwise) that the tumour involves&amp;lt; 4 cm of the gastric wall&lt;/li&gt;&lt;li&gt;The final pre-treatment tumour stage is between T1N0M0 and T4aN1M0, ie, including all stages (T1N0M0, T1N1M0, T1N2M0, T2N0M0, T2N1M0, T2N2M0, T3N0M0, T3N1M0, T3N2M0, T4aN0M0 and T4aN1M0) in which T4a is a resectable tumor invading pleura, pericardium, or diaphragm&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with high grade dysplasia (squamous cell or adenocarcinoma)&lt;/li&gt;&lt;li&gt;Stage 4 disease&lt;/li&gt;&lt;li&gt;Type 3 tumors of the esophago-gastric junction that are scheduled for total gastrectomy&lt;/li&gt;&lt;li&gt;Patients with squamous cell cancer of the esophagus who the MDT recommends or who individually elect to undergo definitive chemoradiotherapy&lt;/li&gt;&lt;li&gt;Evidence of previous complex thoracotomies or laparotomies that preclude a minimal access approach&lt;/li&gt;&lt;li&gt;Evidence of previous/concomitant malignancy that would interfere with this treatment protocol&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;Patients participating in other trials that would interfere with the implementation of this protocol at a particular site&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Assessment of physical function, using the mean of a subscale of the EORTC QLQ-C30, carried out</Description><Timeframe>At 3 and 6 weeks post-surgery and 3 months after randomization</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>All cause short and long term complications</Description></Measure><Measure><Description>Further measures of resource use including: staff time and resources used in theatre in the interventions; subsequent inpatient stays, outpatient visits, general practitioner visits and other community based resource use</Description></Measure><Measure><Description>Generic and disease specific health-related quality of life measures are determined using EORTC QLQ-C30 and QLQ-OES18, multidimensional fatigue inventory (MFI-20), EuroQOLEQ-5D-5L</Description></Measure><Measure><Description>Impact of the 30-day complications will be categorized using the Clavien-Dindo System</Description></Measure><Measure><Description>Length of hospital stay, defined as length of primary hospital stage plus readmission within 30 days (and length of primary hospital stay plus length of hospital stay if discharged to community hospital)</Description></Measure><Measure><Description>Lung function is measured using spirometry measures of forced expiratory volume 1 and forced vital capacity</Description></Measure><Measure><Description>Overall and disease-free survival to two-years</Description></Measure><Measure><Description>Quality assurance of surgery with histopathological and surgical measures-histopathological measures (with the pathologist assessing these blind to treatment allocation): length of the esophagus, total count of malignant 'positive' nodes, total count of all nodes, rates of positive circumferential resection margins, rates of positive proximal and distal resection margins, pT stage (proportions of patients with each pT stage), surgical measures assessed by a surgeon blind to patient allocation, quality of abdominal lymphadenectomy and quality of mediastinal lymphadenectomy</Description></Measure><Measure><Description>Success of blinding during the first 6 days post-surgery is determined using the Bang Blinding Index procedure</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The study hypothesis is that laparoscopically-assisted esophagectomy (LAO) is superior compared to standard open esophagectomy (OO) with respect to recovery from surgery.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will be randomized to either open esophagectomy (OO) or 'laparoscopically assisted' oesophagectomy (LAO) using an internet-based randomization system. Both treatments will be provided as standard on the NHS. OO and LAO both consist of identical steps, except that the abdominal phase of the operation in the LAO group will be done through several smaller cuts to the tummy and performed laparoscopically. The duration of treatment is the duration of surgery.  Patients will be followed-up using questionnaires for 24 to 36 months after randomization into the study (36 month follow-up will only be completed if it falls within the planned length of the study).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Name>Bristol Royal Infirmary</Name><Address1>Bristol</Address1><Address3>BS2 8HW</Address3><Contacts/></Site><Site><Name>Derriford Hospital</Name><Address1>Plymouth</Address1><Address3>PL6 8DH</Address3><Contacts/></Site><Site><Name>Leicester Royal Infirmary</Name><Address1>Leicester</Address1><Address3>LE1 5WW</Address3><Contacts/></Site><Site><Name>Nottingham City Hospital</Name><Address1>Nottingham</Address1><Address3>NG5 1PB</Address3><Contacts/></Site><Site><Name>Royal Infirmary of Edinburgh</Name><Address1>Edinburgh</Address1><Address3>EH16 4SA</Address3><Contacts/></Site><Site><Name>Royal Preston Hospital</Name><Address1>Preston</Address1><Address3>PR2 9HT</Address3><Contacts/></Site><Site><Name>Salford Royal</Name><Address1>Salford</Address1><Address3>M6 8HD</Address3><Contacts/></Site><Site><Name>Southampton General Hospital</Name><Address1>Southampton</Address1><Address3>SO16 6YD</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Esophagus tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="9473">Subjects with Squamous Cell Carcinoma of Esophagus</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9474">Subjects with Adenocarcinoma of Esophagus</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9490">Subjects with Resectable Esophageal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10854">Subjects with Stage I Esophageal Cancer</PatientSegment><SubSegments><SubSegment id="9477">Subjects with stage IA esophageal cancer</SubSegment><SubSegment id="9478">Subjects with stage IB esophageal cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="10855">Subjects with Stage II Esophageal Cancer</PatientSegment><SubSegments><SubSegment id="9479">Subjects with stage IIA esophageal cancer</SubSegment><SubSegment id="9481">Subjects with stage IIB esophageal cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="10856">Subjects with Stage III Esophageal Cancer</PatientSegment><SubSegments><SubSegment id="9482">Subjects with stage IIIA esophageal cancer</SubSegment><SubSegment id="9483">Subjects with stage IIIB esophageal cancer</SubSegment><SubSegment id="9484">Subjects with stage IIIC esophageal cancer</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="ISRCTN">ISRCTN10386621</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Esophagus tumor" id="11970"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Esophagus tumor" id="11973">Assessment by EORTC QLQ-C30 questionnaire</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Esophagus tumor" id="11951"><Endpoint>Assessment of Disease Free Survival (DFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Esophagus tumor" id="11970"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Esophagus tumor" id="11973">Assessment by EORTC QLQ-C30 questionnaire</SubEndpoint><SubEndpoint disease="Esophagus tumor" id="11974">Assessment by EuroQol/EQ-5D questionnaire</SubEndpoint><SubEndpoint disease="Esophagus tumor" id="26580">Assessment by EORTC-esophageal QLQ-OES18</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Esophagus tumor" id="12015"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Esophagus tumor" id="12040">Assessment of complication rate</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Esophagus tumor" id="12023"><Endpoint>Assessment of hospitalization</Endpoint><SubEndpoints><SubEndpoint disease="Esophagus tumor" id="12024">Assessment of duration of hospitalization</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Esophagus tumor" id="12030"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Esophagus tumor" id="12035"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Esophagus tumor" id="12036">Assessment of Efficacy</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Esophagus tumor" id="46079"><Endpoint>Assessment of Fatigue</Endpoint><SubEndpoints><SubEndpoint disease="Esophagus tumor" id="31213">Assessment by Multidimensional Fatigue Inventory (MFI)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Esophagus tumor" id="7747"><Criterion>Subjects with Squamous Cell Carcinoma of Esophagus</Criterion></Inclusion><Inclusion disease="Esophagus tumor" id="7748"><Criterion>Subjects with Adenocarcinoma of Esophagus</Criterion></Inclusion><Inclusion disease="Esophagus tumor" id="7753"><Criterion>Subjects with Stage I Esophageal Cancer</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="7754">Subjects with stage IA esophageal cancer</SubCriterion><SubCriterion disease="Esophagus tumor" id="7755">Subjects with stage IB esophageal cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Esophagus tumor" id="7756"><Criterion>Subjects with Stage II Esophageal Cancer</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="7757">Subjects with stage IIA esophageal cancer</SubCriterion><SubCriterion disease="Esophagus tumor" id="7758">Subjects with stage IIB esophageal cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Esophagus tumor" id="7759"><Criterion>Subjects with Stage III Esophageal Cancer</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="7760">Subjects with stage IIIA esophageal cancer</SubCriterion><SubCriterion disease="Esophagus tumor" id="7761">Subjects with stage IIIB esophageal cancer</SubCriterion><SubCriterion disease="Esophagus tumor" id="7762">Subjects with stage IIIC esophageal cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Esophagus tumor" id="7768"><Criterion>Subjects with Resectable Esophageal Cancer</Criterion></Inclusion><Inclusion disease="Esophagus tumor" id="7770"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Esophagus tumor" id="7791"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="7792">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Esophagus tumor" id="7796">Subjects with history of anti-cancer radiotherapy</SubCriterion><SubCriterion disease="Esophagus tumor" id="7797">Subjects with history of surgery/procedure for esophageal Cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Esophagus tumor" id="34406"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="7809">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Esophagus tumor" id="9310"><Criterion>Subjects with Advanced/Metastatic Esophageal Cancer</Criterion></Exclusion><Exclusion disease="Esophagus tumor" id="9329"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Esophagus tumor" id="9357"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Exclusion><Exclusion disease="Esophagus tumor" id="9369"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="9372">Subjects with medical condition interfering with the study protocol</SubCriterion><SubCriterion disease="Esophagus tumor" id="9379">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Esophagus tumor" id="25494"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="9374">Subjects with prior/current participation in any investigational study</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="estimated">2019-02-28T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>39.00 Months</EnrollmentPeriod><EnrollmentRate>11.44 Patients/Month</EnrollmentRate><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-06-04T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="346803"><TitleDisplay>Phase I/II, Dose-escalation Study to Evaluate Safety, PK and Efficacy of TLC-590 for Postsurgical Pain Management</TitleDisplay><TitleOfficial>A Phase I/II, Randomized, Double-blind, Comparator-controlled, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of TLC-590 for Postsurgical Pain Management Following Inguinal Hernia Repair</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03591146</Identifier><Identifier type="Organisational Study">TLC590A1001</Identifier></Identifiers><Indications><Indication id="20">Pain</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ropivacaine (sustained-release liposomal/BioSeizer, local anesthetic), Taiwan Liposome</Name><Drug id="109181">ropivacaine (sustained-release liposomal/BioSeizer, local anesthetic), Taiwan Liposome</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>ropivacaine</Name><Drug id="4271">ropivacaine</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="109181">ropivacaine (sustained-release liposomal/BioSeizer, local anesthetic), Taiwan Liposome</Drug><IndicationsPioneer><Indication id="20">Pain</Indication></IndicationsPioneer><Companies><Company><Company id="1023258">Taiwan Liposome Co</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1023258" type="Company"><TargetEntity id="4297845612" type="organizationId">Taiwan Liposome Co Ltd</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"/><TargetEntity id="D010146" type="MeSH"/><TargetEntity id="-1585850437" type="omicsDisease"/><TargetEntity id="1" type="siCondition"/></SourceEntity><SourceEntity id="498" type="Action"><TargetEntity id="358" type="Mechanism">Sodium Channel Blockers</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1023258">Taiwan Liposome Co</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="498">Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1669">Local anesthetic</Class><Class id="2946">Analgesic</Class></Class><Technologies><Technology id="654">Intrathecal formulation</Technology><Technology id="142">Liposome formulation</Technology><Technology id="764">Local formulation unspecified</Technology><Technology id="767">Rectal formulation</Technology><Technology id="622">Rectal formulation local</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="589">Sustained release formulation</Technology><Technology id="558">Transdermal formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>64</PatientCountEnrollment><PatientCountEvaluable>64</PatientCountEvaluable><DateStart>2018-07-31T00:00:00Z</DateStart><DateEnd type="actual">2019-01-14T00:00:00Z</DateEnd><DateChangeLast>2019-04-16T05:29:41Z</DateChangeLast><DateAdded>2018-07-20T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Taiwan Liposome Company</Affiliation><Name>Carl Brown, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Able and willing to provide a written informed consent&lt;/li&gt;&lt;li&gt;Male or female between 18 and 65 years of age&lt;/li&gt;&lt;li&gt;Scheduled to undergo a primary, unilateral Lichtenstein inguinal hernia repair with mesh, and be able to use the anesthesia regimen&lt;/li&gt;&lt;li&gt;ASA Physical Status Classification of 1 or 2&lt;/li&gt;&lt;li&gt;Female subjects are eligible only if: not pregnant; not lactating; not planning to become pregnant during the study; commits to the use of an acceptable form of birth control&lt;/li&gt;&lt;li&gt;Male subjects must be sterile or commit to the use of a reliable method of birth control for the duration of the study until at least 1 week after the administration of blinded study medication&lt;/li&gt;&lt;li&gt;Have a body mass index&amp;lt;/=  35 kg/m2&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Clinically significant abnormal clinical laboratory test value&lt;/li&gt;&lt;li&gt;Evidence of a clinically significant 12-lead ECG&lt;/li&gt;&lt;li&gt;History or evidence of orthostatic hypotension, syncope or other syncopal attacks&lt;/li&gt;&lt;li&gt;History or clinical manifestations of significant renal, hepatic, gastrointestinal, cardiovascular, metabolic, neurologic, psychiatric, or other condition&lt;/li&gt;&lt;li&gt;History of seizures or are currently taking anticonvulsants&lt;/li&gt;&lt;li&gt;History of hypersensitivity to ropivacaine, any other amide-type local anesthetic, propofol, hydromorphone or oxycodone (or other opioids)&lt;/li&gt;&lt;li&gt;Persistent or recurrent nausea and/or vomiting due to other etiologies, including, but not limited to gastric outlet obstruction, hypercalcemia, or active peptic ulcer&lt;/li&gt;&lt;li&gt;History of severe or refractory post-operative nausea or vomiting deemed clinically significant&lt;/li&gt;&lt;li&gt;Concurrent painful condition that may require analgesic treatment during the study period&lt;/li&gt;&lt;li&gt;Have been receiving or have received chronic opioid therapy&lt;/li&gt;&lt;li&gt;Use of any of the following medications within five half-lives or as specified prior to the study surgical procedure: Anti-platelet agents such as aspirin therapy within 7 days; clopidogrel within 5 days; Anticoagulants such as warfarin within 5 days; dabigatran etexilate mesylate within 2 days; factor Xa inhibitor within 24 h; Class III antiarrhythmic drugs (eg, amiodarone); Strong CYP1A2 inhibitors, such as cimetidine, ciprofloxacin, enoxacin, and fluvoxamine; CYP1A2 substrates, such as theophylline or imipramine; Strong CYP3A4 inhibitors such as voriconazole, erythromycin, ketoconazole, or ritonavir; CYP3A4 substrates, such as atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, or tipranavir; Corticosteroids, either systemically, inhaled, intranasally, orally, or by intra-articular injection within 14 days before the study surgical procedure (topical corticosteroid is allowed); Non-steroidal anti-inflammatory drugs (NSAIDs) within 14 days prior to the study surgical procedure; Any investigational product within 30 days prior to administration of blinded study medication&lt;/li&gt;&lt;li&gt;History of alcohol abuse or prescription and/or illicit drug abuse within two years&lt;/li&gt;&lt;li&gt;Current report of alcohol abuse within 6 months&lt;/li&gt;&lt;li&gt;Positive results on the urine drug screen or alcohol breath test indicative of illicit drug or alcohol abuse&lt;/li&gt;&lt;li&gt;History of human immunodeficiency virus (HIV), hepatitis C, or hepatitis B&lt;/li&gt;&lt;li&gt;Have had an inguinal hernia repair in the last 3 months before the study surgical procedure or presents with bilateral or recurrent inguinal hernia, other hernia presentations, or hernias with a large scrotal component that would be difficult to reduce surgically&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Safety and tolerability: number of SAEs and treatment-related severe AEs: number of SAEs and treatment-related severe AEs</Description><Timeframe>Screening till 30 days post IP administration</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>AUC of NPRS: AUC of NPRS for time periods 0 to 12, 0 to 24, 0 to 36, 0 to  48, 0 to 72, and 0 to 96 h</Description><Timeframe>For time periods 0 to 12, 0 to 24, 0 to 36, 0 to 48, 0 to 72, and 0 to 96 h</Timeframe></Measure><Measure><Description>Average daily rescue analgesic consumption: average daily rescue analgesic consumption through 24, 48, 72 and 96 h</Description><Timeframe>Baseline till 30 days post IP administration</Timeframe></Measure><Measure><Description>Cumulative proportion of pain-free subjects at scheduled timepoints: pain-free defined as an NPRS of 0 or 1</Description><Timeframe>Baseline till 168 h post IP administration</Timeframe></Measure><Measure><Description>Cumulative proportion of subjects who used no postoperative antiemetic therapy: cumulative proportion of subjects who used no postoperative antiemetic therapy through 12, 24, 36, 48, 72, and 96 h</Description><Timeframe>Baseline till 30 days post IP administration</Timeframe></Measure><Measure><Description>Cumulative proportion of subjects who used no rescue analgesic: cumulative proportion of subjects who used no rescue analgesic through 12, 24, 36, 48, 72, and 96 h</Description><Timeframe>Baseline till 30 days post IP administration</Timeframe></Measure><Measure><Description>Exposure-response relationship between PK parameters and NPRS scores: exposure-response relationship between PK parameters and NPRS scores</Description><Timeframe>Baseline till 168 h post IP administration</Timeframe></Measure><Measure><Description>Incidence of all adverse events by severity and relatedness: incidence of all adverse events by severity and relatedness</Description><Timeframe>Screening till 30 days post IP administration</Timeframe></Measure><Measure><Description>Integrated analgesic score using NPRS score and rescue analgesic consumption: integrated analgesic score using NPRS score and rescue analgesic consumption</Description><Timeframe>Baseline till 30 days post IP administration</Timeframe></Measure><Measure><Description>Pain intensity assessed using an 11-point NPRS ranging: 11-point NPRS ranging from a score of 0 to 10</Description><Timeframe>Baseline till 168 h post IP administration</Timeframe></Measure><Measure><Description>Patient Global Assessment of the method of pain control: Patient Global Assessment: poor, fair, good, or excellent</Description><Timeframe>24 h post IP administration till 168 h post IP administration</Timeframe></Measure><Measure><Description>Proportion of pain-free subjects at scheduled timepoints: pain-free defined as an NPRS of 0 or 1 Baseline till 168 hours post IP administration</Description><Timeframe>Baseline till 168 h post IP administration</Timeframe></Measure><Measure><Description>Time to the first postoperative use of rescue analgesics. Total postoperative consumption of rescue analgesics through 12, 24, 36, 48, 72, and 96 h: time to the first postoperative use of rescue analgesics. Total postoperative consumption of rescue analgesics through 12, 24, 36, 48, 72, and 96 h</Description><Timeframe>Baseline till 30 days post IP administration</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In March 2019,  positive top-line results were presented.  TLC-590 was found to be well tolerated, even at the highest dose, with a safety profile that is comparable to ropivacaine.Â  Nausea, headache, vomiting and constipation were the most commonÂ   treatment-related adverse events observed and were mild;  higher incidents of these mild adverse events were seen in the ropivacaine group.Â  No serious or severe adverse events were observed. There were no adverse events associated with potential local anesthetic systemic toxicity, and no adverse events leading to patient withdrawal [&lt;ulink linkType="Reference" linkID="2128207"&gt;2128207&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a first-in-human, phase I/II, randomized, double-blind, comparator-controlled, dose-escalation study to assess      the safety, PK, and efficacy of single postsurgical application of &lt;ulink linkType="Drug" linkID="109181"&gt;TLC-590&lt;/ulink&gt; compared with      &lt;ulink linkType="Drug" linkID="4271"&gt;Naropin&lt;/ulink&gt; via a single infiltrative local administration in adult subjects following      inguinal hernia repair surgery [&lt;ulink linkType="Reference" linkID="2018814"&gt;2018814&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2063191"&gt;2063191&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2105320"&gt;2105320&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2132870"&gt;2132870&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;As of August 2018, dosing was initiated in first patients (n = 3). A total of 12 subjects were enrolled to date [&lt;ulink linkType="Reference" linkID="2063191"&gt;2063191&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;As of December 2018, enrollment was completed by 64 subjects [&lt;ulink linkType="Reference" linkID="2105320"&gt;2105320&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In March 2019,  positive top-line results were presented. Top-line data showed that all four doses of TLC-590 resulted in greater reductions in pain intensity than ropivacaine as measured by AUC at every interval. There were durable, statistically significant and clinically meaningful reductions in pain intensity with movement compared to ropivacaine, as measured by AUC0-24h (p=0.0057), AUC0-48h (p=0.0131), AUC0-72h (p=0.0117) and AUC0-96h (p=0.0103); the greater levels of pain reduction was maintained through 168 h. Through the entire duration of the study, 58.3% of patients who received TLC-590 475 mg did not use any rescue opioids at all. Time to first postsurgical opioid use was about four times that of the ropivacaine group (median 13.0  versus 3.3 h), among those who did use rescue opioids. Mean total opioid consumption was 54% less through 96 h post-surgery. TLC590 showed  dose-dependent activity based on blood concentration as well as pharmacokinetic markers [&lt;ulink linkType="Reference" linkID="2128207"&gt;2128207&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;ApproximatelyÂ 64 evaluable subjects across      four cohorts in a 3 : 1 ratio (with 12 patients receiving TLC-590 and four patients receiving non-liposomal ropivacaine in each cohort). Dose-escalation of a single postsurgical administration of TLC-590 (contains ropivacaine concentration 19 mg/ml) or Naropin (150 mg [0.5%, 5 mg/ml] x 30 ml) would be performed. Dose-escalation would be      determined by review of treatment-related adverse events  and all serious AEs by a safety monitoring committee. Subjects would undergo follow-up for 30 days after surgery and dosing [&lt;ulink linkType="Reference" linkID="2063191"&gt;2063191&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2105320"&gt;2105320&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received TLC-590Â  at four doses (190, 380, 475 and 570 mg) compared to a standard dose of ropivacaine (150 mg, dose strength equivalent to 90 mg bupivacaine) [&lt;ulink linkType="Reference" linkID="2128207"&gt;2128207&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionControl"><Name>ropivacaine</Name><Drug id="4271">ropivacaine</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="110">Emesis</Indication></AdverseEvent><AdverseEvent><Indication id="148">Headache</Indication></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication></AdverseEvent><AdverseEvent><Indication id="404">Constipation</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>ropivacaine (sustained-release liposomal/BioSeizer, local anesthetic), Taiwan Liposome</Name><Drug id="109181">ropivacaine (sustained-release liposomal/BioSeizer, local anesthetic), Taiwan Liposome</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="110">Emesis</Indication></AdverseEvent><AdverseEvent><Indication id="148">Headache</Indication></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication></AdverseEvent><AdverseEvent><Indication id="404">Constipation</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="829230">ropivacaine</Intervention><Treatments><Treatment><Dose>150 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="829231">ropivacaine (sustained-release liposomal/BioSeizer, local anesthetic), Taiwan Liposome</Intervention><Treatments><Treatment><Dose>190 milligram</Dose><Route></Route></Treatment><Treatment><Dose>380 milligram</Dose><Route></Route></Treatment><Treatment><Dose>475 milligram</Dose><Route></Route></Treatment><Treatment><Dose>570 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>JBR Clinical Research</Name><Address1>Draper</Address1><Address2>Utah</Address2><Address3>84020</Address3><CountrySubDivision code="UT">Utah</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8424">Subjects with Post-Operative Pain</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8425">Subjects in need of Procedural Analgesia</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03591146</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="26032"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26034">Assessment of serious adverse events</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="26033"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="37190"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pain" id="25871"><Endpoint>Assessment of Pain at Rest</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25875">Based on Numerical Rating Scale [NRS]</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25894"><Endpoint>Assessment of Response Rates (RR)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25984"><Endpoint>Assessment by Global Assessment Scales</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26000"><Endpoint>Assessment of Pain</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26007"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26032"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26033"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26038"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26044">Assessment of analgesic use/rescue medication</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26058"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26061">Other post-operative outcomes</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="34784"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="37190"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="43194">Area under concentration curve (AUC)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Pain" id="25934"><Endpoint>Assessment of Post-operative Pain</Endpoint></OtherEndpoint><OtherEndpoint disease="Pain" id="26038"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26039">Assessment of efficacy</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Pain" id="37190"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="43193">Assessment of maximum concentration of drug (Cmax)</SubEndpoint><SubEndpoint disease="Pain" id="43194">Area under concentration curve (AUC)</SubEndpoint><SubEndpoint disease="Pain" id="43196">Time to maximum concentration (Tmax)</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22141"><Criterion>Subjects in Need of Procedural Analgesia</Criterion></Inclusion><Inclusion disease="Pain" id="22142"><Criterion>Subjects with Peri-operative Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22143">Subjects with post operative pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22172"><Criterion>Subjects with Normal/Acceptable Clinical Assessments</Criterion><SubCriteria><SubCriterion disease="Pain" id="22173">Subjects with pre-specified physical status</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22175"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion></Inclusion><Inclusion disease="Pain" id="22252"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion><SubCriteria><SubCriterion disease="Pain" id="22256">Subjects with history/scheduled for surgery for other indication</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22262"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Pain" id="22267">Protocol specified inclusion criteria for women</SubCriterion><SubCriterion disease="Pain" id="22268">Protocol specified inclusion criteria for men</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="34371"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="22263">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="34827"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="22264">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="34957"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20095"><Criterion>Subjects with Abnormal/Unacceptable Clinical Assessments</Criterion></Exclusion><Exclusion disease="Pain" id="20104"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Pain" id="20113">Subjects co-morbid with metabolic diseases/disorders</SubCriterion><SubCriterion disease="Pain" id="20114">Subjects co-morbid with CNS disorders/diseases</SubCriterion><SubCriterion disease="Pain" id="20123">Subjects with infectious disorders/disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20115"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Pain" id="20117"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Pain" id="20120"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Pain" id="20125"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion><SubCriteria><SubCriterion disease="Pain" id="20127">Hypersensitivity/ contraindication to local anaesthesia/ blocks</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20131"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="20132">Subjects with history/scheduled to receive opioids</SubCriterion><SubCriterion disease="Pain" id="20133">Subjects with history of NSAIDs</SubCriterion><SubCriterion disease="Pain" id="20135">Subjects with history/scheduled to receive steroids</SubCriterion><SubCriterion disease="Pain" id="20138">Subjects with history/scheduled to receive anti-convulsants</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20182"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Pain" id="20188">Subjects unsuitable for study participation as per investigator's assessment</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="24893"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pain" id="20128">Hypersensitivity/ contraindication to general anaesthesia</SubCriterion><SubCriterion disease="Pain" id="20129">Hypersensitivity/ contraindication to investigational drug/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="25794"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="20154">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="26044"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Pain" id="20116">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="26300"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Pain" id="20108">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="27443"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Pain" id="27926"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="20184">Unwillingness to comply with protocol requirements</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="29411"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2019-01-05T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2018-12-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>5.03 Months</EnrollmentPeriod><EnrollmentRate>12.72 Patients/Month</EnrollmentRate><DateFirstReceived>2018-06-25T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-07-20T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-08-23T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-03-16T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="Added"><Date>2019-03-16T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-16T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-16T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-16T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-16T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-16T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-16T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-16T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="added"><Date>2019-03-16T00:00:00Z</Date><Reason id="308">Protocol &amp; Results section added</Reason></Change><Change type="added"><Date>2019-03-16T00:00:00Z</Date><Reason id="308">Protocol &amp; Results section added</Reason></Change><Change type="added"><Date>2019-03-16T00:00:00Z</Date><Reason id="308">Protocol &amp; Results section added</Reason></Change><Change type="added"><Date>2019-03-16T00:00:00Z</Date><Reason id="311">Trial Treatment added</Reason></Change><Change type="added"><Date>2019-03-16T00:00:00Z</Date><Reason id="311">Trial Treatment added</Reason></Change><Change type="added"><Date>2019-03-16T00:00:00Z</Date><Reason id="311">Trial Treatment added</Reason></Change><Change type="added"><Date>2019-03-16T00:00:00Z</Date><Reason id="311">Trial Treatment added</Reason></Change><Change type="added"><Date>2019-03-16T00:00:00Z</Date><Reason id="311">Trial Treatment added</Reason></Change><Change type="updated"><Date>2019-03-27T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-04-15T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-04-15T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-04-15T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change><Change type="updated"><Date>2019-04-15T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change><Change type="removed"><Date>2019-04-15T00:00:00Z</Date><Reason id="317">Trial Outcome Measure Removed</Reason></Change><Change type="removed"><Date>2019-04-15T00:00:00Z</Date><Reason id="317">Trial Outcome Measure Removed</Reason></Change><Change type="removed"><Date>2019-04-15T00:00:00Z</Date><Reason id="317">Trial Outcome Measure Removed</Reason></Change><Change type="removed"><Date>2019-04-15T00:00:00Z</Date><Reason id="317">Trial Outcome Measure Removed</Reason></Change><Change type="removed"><Date>2019-04-15T00:00:00Z</Date><Reason id="317">Trial Outcome Measure Removed</Reason></Change><Change type="updated"><Date>2019-04-16T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-04-16T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="48777"><TitleDisplay>Bortezomib, Ifosfamide, Carboplatin and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma</TitleDisplay><TitleOfficial>Safety and Efficacy Pilot Trial of the Anti-viral and Anti-tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-associated Non-hodgkin's Lymphoma</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">U01CA121947</Identifier><Identifier type="Organisational Study">CDR0000581078</Identifier><Identifier type="NCT">NCT00598169</Identifier><Identifier type="Secondary Organisational">AMC-053</Identifier></Identifiers><Indications><Indication id="319">Non-Hodgkin lymphoma</Indication><Indication id="4">Acquired immune deficiency syndrome</Indication></Indications><BiomarkerNames><BiomarkerName id="1731" role="Disease marker" type="Genomic;Proteomic">B-lymphocyte antigen CD20</BiomarkerName><BiomarkerName id="6343" role="Therapeutic effect marker" type="Genomic;Proteomic">DNA dC-&gt;dU-editing enzyme APOBEC-3G</BiomarkerName><BiomarkerName id="30572" role="Therapeutic effect marker" type="Cellular">Mononuclear leukocytes</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>bortezomib</Name><Drug id="15954">bortezomib</Drug></Intervention><Intervention type="InterventionPrimary"><Name>bortezomib + etoposide + carboplatin + ifosfamide + rituximab</Name></Intervention><Intervention type="InterventionPrimary"><Name>carboplatin</Name><Drug id="44383">carboplatin</Drug></Intervention><Intervention type="InterventionPrimary"><Name>dexamethasone</Name></Intervention><Intervention type="InterventionPrimary"><Name>etoposide phosphate</Name><Drug id="3072">etoposide phosphate</Drug></Intervention><Intervention type="InterventionPrimary"><Name>ifosfamide</Name></Intervention><Intervention type="InterventionPrimary"><Name>mesna</Name><Drug id="24142">mesna</Drug></Intervention><Intervention type="InterventionPrimary"><Name>rituximab</Name><Drug id="6736">rituximab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="15954">bortezomib</Drug><IndicationsPioneer><Indication id="4">Acquired immune deficiency syndrome</Indication></IndicationsPioneer><Companies><Company><Company id="1038724">The EMMES Corp</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1039248">AIDS Associated Malignancies Clinical Trials Consortium</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="24142">mesna</Drug><IndicationsPioneer><Indication id="4">Acquired immune deficiency syndrome</Indication></IndicationsPioneer><Companies><Company><Company id="1038724">The EMMES Corp</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1039248">AIDS Associated Malignancies Clinical Trials Consortium</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3072">etoposide phosphate</Drug><IndicationsPioneer/><Companies><Company><Company id="1038724">The EMMES Corp</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1039248">AIDS Associated Malignancies Clinical Trials Consortium</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44383">carboplatin</Drug><IndicationsPioneer><Indication id="4">Acquired immune deficiency syndrome</Indication></IndicationsPioneer><Companies><Company><Company id="1038724">The EMMES Corp</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1039248">AIDS Associated Malignancies Clinical Trials Consortium</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6736">rituximab</Drug><IndicationsPioneer/><Companies><Company><Company id="1038724">The EMMES Corp</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1039248">AIDS Associated Malignancies Clinical Trials Consortium</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="44383" type="Drug"><TargetEntity id="125568" type="siDrug">Carboplatin</TargetEntity></SourceEntity><SourceEntity id="6736" type="Drug"><TargetEntity id="204337" type="siDrug">Rituximab</TargetEntity></SourceEntity><SourceEntity id="15954" type="Drug"><TargetEntity id="260757" type="siDrug">Bortezomib</TargetEntity></SourceEntity><SourceEntity id="24142" type="Drug"><TargetEntity id="281496" type="siDrug">Mesna</TargetEntity></SourceEntity><SourceEntity id="1038724" type="Company"><TargetEntity id="5035542542" type="organizationId">Emmes Corp</TargetEntity></SourceEntity><SourceEntity id="1039248" type="Company"><TargetEntity id="5035542487" type="organizationId">Aids Associated Malignancies Clinical Trials Consortium</TargetEntity></SourceEntity><SourceEntity id="20519" type="Company"><TargetEntity id="4296539077" type="organizationId">National Cancer Institute</TargetEntity></SourceEntity><SourceEntity id="319" type="ciIndication"><TargetEntity id="10029547" type="MEDDRA"/><TargetEntity id="D008228" type="MeSH"/><TargetEntity id="547" type="ORPHANET"/><TargetEntity id="-1008757452" type="omicsDisease"/><TargetEntity id="703" type="siCondition"/></SourceEntity><SourceEntity id="4" type="ciIndication"><TargetEntity id="10000565" type="MEDDRA"/><TargetEntity id="D000163" type="MeSH"/><TargetEntity id="-956122641" type="omicsDisease"/><TargetEntity id="1124" type="siCondition"/></SourceEntity><SourceEntity id="142" type="Action"><TargetEntity id="419" type="Mechanism">DNA Topoisomerase II Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4917" type="Action"><TargetEntity id="1125" type="Mechanism">Proteasome Inhibitors</TargetEntity><TargetEntity id="3073" type="Mechanism">Immunoproteasome Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>16</NumberOfSites><CompaniesSponsor><Company id="1039248">AIDS Associated Malignancies Clinical Trials Consortium</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1038724">The EMMES Corp</Company><Company id="20519">National Cancer Institute</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="142">Topoisomerase II inhibitor</Action><Action id="4917">Proteasome inhibitor</Action><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action><Action id="76469">26S proteasome complex inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="140">DNA synthesis inhibitor</Class><Class id="1545">Anticancer</Class><Class id="1589">Apoptosis stimulator</Class><Class id="2953">Anti-inflammatory</Class><Class id="50">Anticancer alkylating agent</Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="59620">Unspecified drug target</Class><Class id="959">Protectant</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="166">Chimeric monoclonal antibody</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="596">Injectable formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="85">Protein recombinant</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="603">Systemic formulation unspecified</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>23</PatientCountEnrollment><PatientCountEvaluable>23</PatientCountEvaluable><DateStart>2007-11-30T00:00:00Z</DateStart><DateEnd type="actual">2014-11-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-14T02:33:01Z</DateChangeLast><DateAdded>2009-04-02T07:47:15Z</DateAdded><Contacts><Contact type="Scientific contact"><Name>David Aboulafia</Name></Contact><Contact type="Scientific contact"><Name>Robert Baiocchi</Name></Contact><Contact type="Scientific contact"><Name>Stephan Barta</Name></Contact><Contact type="Scientific contact"><Name>Amanda Hutchison-Rzepka</Name></Contact><Contact type="Scientific contact"><Name>Yvette Kasamon</Name></Contact><Contact type="Scientific contact"><Name>Mary Lechowicz</Name></Contact><Contact type="Scientific contact"><Name>Martha Mimms</Name></Contact><Contact type="Scientific contact"><Affiliation>University of California, San Diego</Affiliation><Name>Erin G. Reid, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>University of California, San Diego</Affiliation><Name>William Wachsman, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Disease characteristics&lt;ul&gt;&lt;li&gt;Histologically or cytologically confirmed relapsed or refractory HIV-associated             non-Hodgkin lymphoma (NHL)&lt;ul&gt;&lt;li&gt;Must have histological or cytological documentation of prior AIDS-associated NHL                  (ie, at time of diagnosis) for clinically relapsed and/or refractory disease                  for which biopsy is not feasible&lt;/li&gt;&lt;li&gt;Must have documented HIV seropositivity&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Must have documentation of Epstein-Barr Virus (EBV)- and/or human herpes virus-8                  (HHV-8)- positive infection within the lymphoma (ie, LMP-1 or LANA expression                  or positive Epstein-Barr-encoded RNAs [EBERs])&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patient characteristics:&lt;ul&gt;&lt;li&gt;ECOG performance status (PS) 0 to 1 or Karnofsky PS 70 to 100%&lt;/li&gt;&lt;li&gt;Life expectancy&amp;gt; 2 months&lt;/li&gt;&lt;li&gt;ANC &gt;/= 1000/microl (growth factor support allowed)&lt;/li&gt;&lt;li&gt;Hemoglobin &gt;/= 8.0 g/dl (growth factor support allowed)&lt;/li&gt;&lt;li&gt;Platelet count &gt;/= 100,000/microl&lt;/li&gt;&lt;li&gt;Total bilirubin&amp;lt;/= 1.5 mg/dl&lt;/li&gt;&lt;li&gt;AST/ALT&amp;lt;/= 2.5 times institutional upper limit of normal&lt;/li&gt;&lt;li&gt;Creatinine clearance &gt;/= 50 ml/min&lt;/li&gt;&lt;li&gt;Negative pregnancy test&lt;/li&gt;&lt;li&gt;Not pregnant or nursing&lt;/li&gt;&lt;li&gt;Fertile patients must use effective contraception. Patients with lymphomatous             involvement of the bone unable to meet hematological criteria are allowed&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Peripheral neuropathy &gt;/= grade 2&lt;/li&gt;&lt;li&gt;Uncontrolled intercurrent illness including, but not limited to, any of the             following:&lt;ul&gt;&lt;li&gt;Ongoing or active infection&lt;/li&gt;&lt;li&gt;Opportunistic infections controlled by antimicrobial or suppressive therapy                       allowed, unless the investigator judges the infection likely to become                       life-threatening in the setting of multi-agent chemotherapy&lt;/li&gt;&lt;li&gt;Symptomatic congestive heart failure&lt;/li&gt;&lt;li&gt;Unstable angina pectoris&lt;/li&gt;&lt;li&gt;NYHA class III or IV heat failure&lt;/li&gt;&lt;li&gt;Myocardial infarction within the past 6 months&lt;/li&gt;&lt;li&gt;Uncontrolled angina&lt;/li&gt;&lt;li&gt;Severe uncontrolled ventricular or other cardiac arrhythmias&lt;/li&gt;&lt;li&gt;Acute ischemia or active conduction system abnormalities by ECG&lt;/li&gt;&lt;li&gt;Serious psychiatric or medical illness, that would interfere with study                  compliance&lt;/li&gt;&lt;li&gt;Social situations that would interfere with study compliance&lt;/li&gt;&lt;li&gt;Acute active HIV-associated opportunistic infection requiring antibiotic treatment&lt;/li&gt;&lt;li&gt;Mycobacterium avium or candidiasis allowed unless concurrent therapy with                  moderate-to-strong CYP3A4 inducers or inhibitors is required&lt;/li&gt;&lt;li&gt;Chronic myelosuppressive agent therapy allowed provided hematological criteria are                  met&lt;/li&gt;&lt;li&gt;Hypersensitivity to compounds of similar chemical or biological composition to&lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt;, boron, mannitol, ifosfamide, &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt;, or &lt;ulink linkType="Drug" linkID="3072"&gt;etoposide&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Concurrent malignancy except carcinoma in situ of the cervix, nonmetastatic             nonmelanomatous skin cancer, or Kaposi's sarcoma not requiring systemic chemotherapy&lt;/li&gt;&lt;li&gt;Active hepatitis B infection (hepatitis B surface antigen-positive), unless one of the             following criteria are met:&lt;ul&gt;&lt;li&gt;Able to start dual anti-hepatitis B adefovir and telbivudine therapy prior to                  study&lt;/li&gt;&lt;li&gt;Receiving dual anti-hepatitis B therapy for at least 12 weeks prior to study with                  either agent active against HIV (ie, entecavir, tenofovir, lamivudine, or                  emtricitabine)&lt;/li&gt;&lt;li&gt;Concurrent grapefruit juice/fruit or green tea prior concurrent therapy:&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;See disease characteristics&lt;/li&gt;&lt;li&gt;Recovered from prior adverse effects due to agents administered more than 3 weeks             earlier&lt;/li&gt;&lt;li&gt;Glucocorticoid therapy within the past 3 weeks allowed&lt;/li&gt;&lt;li&gt;With &gt; 3 weeks since prior chemotherapy&lt;/li&gt;&lt;li&gt;With &gt; 2 weeks since prior radiotherapy&lt;/li&gt;&lt;li&gt;With &gt;  14 days since prior and no other concurrent investigational agents (other             than&lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt;)&lt;/li&gt;&lt;li&gt;No concurrent moderate-to-strong CYP3A4 inducers or inhibitors other than protease             inhibitors&lt;/li&gt;&lt;li&gt;Concurrent stable (at least 12 weeks) antiretroviral regimen allowed&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Maximum tolerated dose of bortezomib</Description><Timeframe>Assessed at end of cycle 1 for each group of three subjects</Timeframe></Measure><Measure><Description>Overall lymphoma response rate</Description><Timeframe>End of treatment</Timeframe></Measure><Measure><Description>Safety as assessed using the CTCAE</Description><Timeframe>Every cycle of treatment and all post-treatment visits</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Median overall survival at one year</Description><Timeframe>One year post-treatment</Timeframe></Measure><Measure><Description>Impact of bortezomib alone and in combination with rituximab,  ifosfamide, carboplatin, and etoposide (R) ICE on serum HIV viral loads and APOBEC3G levels</Description><Timeframe>Baseline, days 2, 4, and 8 of week 1 of part A, end of treatment</Timeframe></Measure><Measure><Description>Impact of bortezomib alone and in combination with (R)ICE on EBV and HHV-8 lytic activation using serum viral loads</Description><Timeframe>Baseline, days 2, 4, and 8 of week 1 of part A, end of treatment</Timeframe></Measure><Measure><Description>Safety of bortezomib alone in patients with relapsed or refractory AIDS-associated lymphomas</Description><Timeframe>Every cycle of treatment and all post-treatment visits</Timeframe></Measure><Measure><Description>Correlation of  EBV/HHV-8 viral load changes with lymphoma response</Description><Timeframe>Baseline, days 2, 4, and 8 of week 1 of part A, end of treatment</Timeframe></Measure><Measure><Description>Comparison of above outcomes to a parallel protocol employing ICE +/- rituximab in patients with EBV/HHV-8-negative AIDS-NHL to assess whether bortezomib has additional effects beyond (R)ICE alone</Description><Timeframe>Upon availability of both studies' results</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In December 2016, results were were presented.  Grade 3 to 4 toxicities included anemia, febrile neutropenia, leucopenia, lymphopenia, neutropenia, thrombocytopenia, dyspnea, hypokalemia, hyponatremia, hypophosphatemia, hypotension, neuralgia and syncope [&lt;ulink linkType="Reference" linkID="1881740"&gt;1881740&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this clinical trial was to study giving &lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt; together with dexamethasone,      ifosfamide, &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt;, and &lt;ulink linkType="Drug" linkID="3072"&gt;etoposide&lt;/ulink&gt; to see how well it works with or without &lt;ulink linkType="Drug" linkID="6736"&gt;rituximab&lt;/ulink&gt; in      treating patients with relapsed or refractory AIDS-related non-Hodgkin lymphoma.&lt;/para&gt;&lt;para&gt;The primary objective was to evaluate the safety and overall lymphoma response rate of &lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt; in combination with           ifosfamide, &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt;, and &lt;ulink linkType="Drug" linkID="3072"&gt;etoposide&lt;/ulink&gt; (ICE) with or without &lt;ulink linkType="Drug" linkID="6736"&gt;rituximab&lt;/ulink&gt; in patients with           Epstein-Barr Virus (EBV)- and/or human herpes virus-8 (HHV-8)- positive relapsed or           refractory HIV-associated non-Hodgkin lymphoma (NHL).&lt;/para&gt;&lt;para&gt;The      secondaryobjectives were to:&lt;br/&gt;Evaluate the impact of &lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt; alone and in combination with &lt;ulink linkType="Drug" linkID="6736"&gt;rituximab&lt;/ulink&gt; (R)  and ICE           ([R] ICE) on serum HIV viral loads and APOBEC3G levels.&lt;br/&gt;Estimate the impact of &lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt; alone and in combination with (R)ICE on EBV and HHV-8           lytic activation using serum viral loads.&lt;br/&gt;Evaluate the safety of &lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt; alone in patients with relapsed or refractory           AIDS-associated lymphomas.&lt;br/&gt;Correlate EBV/HHV-8 viral load changes with lymphoma response.&lt;br/&gt;Compare the above outcomes to a parallel protocol employing ICE with or without           &lt;ulink linkType="Drug" linkID="6736"&gt;rituximab&lt;/ulink&gt; in patients with EBV/HHV-8-negative AIDS-NHL to assess whether &lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt; has           additional effects beyond (R)ICE alone.&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In December 2016, results were were presented.  The maximum tolerated dose was not reached at the highest dose cohort studied (bortezomib 1.5 mg/m2). Responses occurred in 14/22 patients initiating protocol therapy: five complete and nine partial responses. Of the 20 patients who completed two or more cycles, the overall response rate was 80% and the one-year overall survival rate was 55%. After bortezomib alone, median values of EBV PBMC viral load measured on day 8 were 2 x greater than baseline. There was no correlation found between change in EBV viral load and response [&lt;ulink linkType="Reference" linkID="1881740"&gt;1881740&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This would be a multicenter, dose-escalation study of &lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt;. Patients would be assigned to one of two treatment groups:&lt;/para&gt;&lt;para&gt;CD20+ Non-Hodgkin Lymphoma group:&lt;br/&gt;Part A: patients would receive Velcade (&lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt;) on days 1 and 8, with inter-patient dose escalation over four dose levels: 0.7, 1, 1.3 and 1.5 mg/m2. Dexamethasone 20 mg iv and &lt;ulink linkType="Drug" linkID="3072"&gt;etoposide&lt;/ulink&gt; 100 mg/m2 iv on days 8 to 10, &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; dosed to AUC = 5 (maximum 750 mg) iv and ifosfamide 5000 mg/m2 mixed with an equal amount of &lt;ulink linkType="Drug" linkID="24142"&gt;mesna&lt;/ulink&gt; on day 9 of a 28-day cycle.&lt;/para&gt;&lt;para&gt;Part B: patients would receive Velcade (&lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt;) on days 1 and 8, dexamethasone 20 mg iv on days 1 to 3 and day 8; &lt;ulink linkType="Drug" linkID="3072"&gt;etoposide&lt;/ulink&gt; 100 mg/m2 iv on days 1 to 3; &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; dosed to AUC = 5 (maximum 750 mg) iv on day 2; ifosfamide 5000 mg/m2 mixed with an equal amount of &lt;ulink linkType="Drug" linkID="24142"&gt;mesna&lt;/ulink&gt; and administered as a continuous iv infusion over 24 h on day 2, rituximab 375mg/m2 on day 1 of a 21-day cycle.&lt;/para&gt;&lt;para&gt;CD20- Non-Hodgkin Lymphoma group:&lt;br/&gt;Part A: patients would receive Velcade (&lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt;) over 3 to 5 s on days 1 and 8, with inter-patient dose escalation over four dose levels: 0.7, 1, 1.3 and 1.5 mg/m2. Dexamethasone 20 mg iv and &lt;ulink linkType="Drug" linkID="3072"&gt;etoposide&lt;/ulink&gt; 100 mg/m2 iv over 2 h on days 8 to 10, &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; dosed to AUC = 5 (maximum 750 mg) iv  over 2 h and ifosfamide 5000 mg/m2 iv continuously over 24-h mixed with an equal amount of &lt;ulink linkType="Drug" linkID="24142"&gt;mesna&lt;/ulink&gt; on day 9 of a 28-day cycle.&lt;/para&gt;&lt;para&gt;Part B: patients would receive Velcade (&lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt;) over 3 to 5 s on days 1 and 8, dexamethasone 20 mg iv on days 1 to 3 and day 8; &lt;ulink linkType="Drug" linkID="3072"&gt;etoposide&lt;/ulink&gt; 100 mg/m2 iv over 2 h on days 1 to 3; &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; dosed to AUC=5 (maximum 750 mg) iv over 2 h on day 2; ifosfamide 5000 mg/m2 iv continuously over 24 h mixed with an equal amount of &lt;ulink linkType="Drug" linkID="24142"&gt;mesna&lt;/ulink&gt; and administered as a continuous iv infusion over 24 h on day 2, rituximab 375mg/m2 on day 1 of a 21-day cycle.&lt;/para&gt;&lt;para&gt;EBV/HHV-8 viral load changes with lymphoma response would be correlated. HIV and EBV/HHV-8 viral loads would be assessed on baseline, day 2, 4, and 8 of week 1 of Part A. Peripheral blood mononuclear cells would be collected at day 1 prior to chemotherapy, day 2, 4 and 8 (prior to chemotherapy) then weekly during Part A, just prior to each additional cycle of Part B and at treatment completion. Western blot using antibody specific for APOBEC3G and antibody against actin for internal control would be used to quantify APOBEC3G levels. Changes at would be compared with baseline using a paired t-test. Patients would undergo blood sample collection periodically for correlative studies. Samples would be analyzed for the effects of &lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt; on viral activation and replication via Taqman polymerase chain reaction (PCR), and to quantify APOBEC3G levels via western blot. Similar studies would be performed on the BCLB-1 EBV containing lines, as well as Daudi and other EBV-transformed B-lymphocyte lines via quantitative viral DNA PCR. Patients would complete the Functional Assessment of Cancer Therapy/GOG-Neurotoxicity questionnaire, at day 8 and week 4 of part A and at least once per course of Part B for assessment of neuropathic pain and/or peripheral neuropathy. After completion of study treatment, patients achieving complete response (CR) would be followed at 2 to 4  weeks, every 3 months for one year. Patients not achieving CR at completion of study treatment and declining further antineoplastic treatment, would be followed at 2 to 4 weeks and then every 3 months for one year.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Bortezomib was given iv on day 1 and 8 of each cycle at one of 4 dose levels: 0.7, 1, 1.3 or 1.5 mg/m2.  Standard dose ICE +/ - R (ifosfamide, carboplatin,Â etoposide +/- rituximab) began day 8 of cycle 1 (28-day cycle); ICE +/- R began day 1 of all subsequent cycles (21-day cycle) [&lt;ulink linkType="Reference" linkID="1881740"&gt;1881740&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>bortezomib + etoposide + carboplatin + ifosfamide + rituximab</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="1256">Hyponatremia</Indication></AdverseEvent><AdverseEvent><Indication id="1280">Hypophosphatemia</Indication></AdverseEvent><AdverseEvent><Indication id="1295">Neuropathic pain</Indication></AdverseEvent><AdverseEvent><Indication id="17">Anemia</Indication></AdverseEvent><AdverseEvent><Indication id="181">Hypokalemia</Indication></AdverseEvent><AdverseEvent><Indication id="1876">Syncope</Indication></AdverseEvent><AdverseEvent><Indication id="1991">Neutropenia</Indication></AdverseEvent><AdverseEvent><Indication id="1992">Lymphocytopenia</Indication></AdverseEvent><AdverseEvent><Indication id="2400">Dyspnea</Indication></AdverseEvent><AdverseEvent><Indication id="324">Thrombocytopenia</Indication></AdverseEvent><AdverseEvent><Indication id="3795">Febrile neutropenia</Indication></AdverseEvent><AdverseEvent><Indication id="408">Hypotension</Indication></AdverseEvent><AdverseEvent><Indication id="680">Leukopenia</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="112285">bortezomib</Intervention><Treatments><Treatment><Dose>0.7 milligram/m2</Dose><Route></Route></Treatment><Treatment><Dose>1 milligram/m2</Dose><Route></Route></Treatment><Treatment><Dose>1.3 milligram/m2</Dose><Route></Route></Treatment><Treatment><Dose>1.5 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="112286">carboplatin</Intervention><Treatments><Treatment><Dose>750 milligram</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="112287">dexamethasone</Intervention><Treatments><Treatment><Dose>20 milligram</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="112288">etoposide phosphate</Intervention><Treatments><Treatment><Dose>100 milligram/m2</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="112289">ifosfamide</Intervention><Treatments><Treatment><Dose>5000 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center</Name><Address1>Columbus</Address1><Address2>Ohio</Address2><Address3>43210-1240</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>Baylor College of Medicine</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77030-2707</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Cancer Research Center of Hawaii</Name><Address1>Honolulu</Address1><Address2>Hawaii</Address2><Address3>96813</Address3><CountrySubDivision code="HI">Hawaii</CountrySubDivision><Contacts/></Site><Site><Name>Emory Winship Cancer Institute</Name><Address1>Atlanta</Address1><Address2>Georgia</Address2><Address3>30322</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts/></Site><Site><Name>Memorial Sloan-Kettering Cancer Center</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10065</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>Montefiore Medical Center</Name><Address1>Bronx</Address1><Address2>New York</Address2><Address3>10467-2490</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>Northwestern Cancer Center</Name><Address1>Chicago</Address1><Address2>Illinois</Address2><Address3>60611</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Name>Pennsylvania Oncology Hematology Associates, Incorporated - Philadelphia</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><Address3>19106</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts/></Site><Site><Name>Rebecca and John Moores UCSD Cancer Center</Name><Address1>La Jolla</Address1><Address2>California</Address2><Address3>92093-0658</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</Name><Address1>Baltimore</Address1><Address2>Maryland</Address2><Address3>21231-2410</Address3><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts/></Site><Site><Name>Thomas Street Health Center</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77009</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>UCLA Clinical AIDS Research and Education (CARE) Center</Name><Address1>Los Angeles</Address1><Address2>California</Address2><Address3>90095-1793</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>USC/Norris Comprehensive Cancer Center and Hospital</Name><Address1>Los Angeles</Address1><Address2>California</Address2><Address3>90089-9181</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>University of California at Davis Center for Aids Research and Education Services</Name><Address1>Sacramento</Address1><Address2>California</Address2><Address3>95814</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>University of Miami Sylvester Comprehensive Cancer Center - Miami</Name><Address1>Miami</Address1><Address2>Florida</Address2><Address3>33136</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Virginia Mason Medical Center</Name><Address1>Seattle</Address1><Address2>Washington</Address2><Address3>98101</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site><Site><Name>Baylor University Medical Center - Houston</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3> 77030-2707</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Cancer Research Center of Hawaii</Name><Address1>Honolulu</Address1><Address2>Hawaii</Address2><Address3> 96813</Address3><CountrySubDivision code="HI">Hawaii</CountrySubDivision><Contacts/></Site><Site><Name>Emory - Winship Cancer Institute</Name><Address1>Atlanta</Address1><Address2>Georgia</Address2><Address3> 30322</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts/></Site><Site><Name>Montefiore Medical Center</Name><Address1>Bronx</Address1><Address2>New York</Address2><Address3> 10467-2490</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>Northwestern Cancer Center</Name><Address1>Chicago</Address1><Address2>Illinois</Address2><Address3> 60611</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Name>Pennsylvania Oncology Hematology Associates, Incorporated - Philadelphia</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><Address3> 19106</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts/></Site><Site><Name>Rebecca and John Moores UCSD Cancer Center</Name><Address1>La Jolla</Address1><Address2>California</Address2><Address3> 920930658</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>USC - Norris Comprehensive Cancer Center and Hospital</Name><Address1>Los Angeles</Address1><Address2>California</Address2><Address3> 90089-9181</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Virginia Mason Medical Center</Name><Address1>Seattle</Address1><Address2>Washington</Address2><Address3> 98101</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Lymphoma</Disease><PatientSegments><PatientSegment><PatientSegment id="3489">Subjects with B Cell Non Hodgkin's Lymphoma</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3490">Subjects with T Cell Non Hodgkin's Lymphoma</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3512">Subjects with Other Lymphoid Malignancies</PatientSegment><SubSegments><SubSegment id="3513">Subjects with HIV associated lymphoma</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3525">Subjects with Relapse/Recurrent Lymphoma</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3530">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>HIV infection</Disease><PatientSegments><PatientSegment><PatientSegment id="7085">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="7381">Subjects with cancer</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Herpesvirus infection</Disease><PatientSegments><PatientSegment><PatientSegment id="10765">Subjects with Epstein-Barr Virus Infections</PatientSegment><SubSegments><SubSegment id="10767">Subjects with lymphoma/lymphoproliferative disorders</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="19020">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="10776">Subjects with HIV Infection</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00598169</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Lymphoma" id="7604"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7611">Assessment of tumor response rate (Duration of response)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Lymphoma" id="7711"><Endpoint>Assessment of Viral Load</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Lymphoma" id="7775"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="9133">Assessment of maximum tolerated dose (MTD)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="HIV infection" id="9212"><Endpoint>Assessment of Viral Load</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="HIV infection" id="9235"><Endpoint>Assessment of Markers of Co-infection</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="HIV infection" id="9246"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Herpesvirus infection" id="16812"><Endpoint>Assessment of Clinical Response</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Herpesvirus infection" id="16837"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Herpesvirus infection" id="16846"><Endpoint>Hematological Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Herpesvirus infection" id="30886"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Herpesvirus infection" id="30934">Other patient reported outcomes</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Lymphoma" id="7538"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7604"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7573">Assessment of therapeutic response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7651"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="28768">Assessment by Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity questionnaire (FACT/GOG-Ntx)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7679"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7711"><Endpoint>Assessment of Viral Load</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7768"><Endpoint>Assessment of Biomarkers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7845"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7868">Assessment of Efficacy</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="HIV infection" id="9212"><Endpoint>Assessment of Viral Load</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="HIV infection" id="9218"><Endpoint>Assessment of Immune Response</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="HIV infection" id="9246"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="HIV infection" id="9270"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Herpesvirus infection" id="16789"><Endpoint>Assessment of Viral Load</Endpoint><SubEndpoints><SubEndpoint disease="Herpesvirus infection" id="16791">Viral load of EBV</SubEndpoint><SubEndpoint disease="Herpesvirus infection" id="16794">Viral load of KSHV</SubEndpoint><SubEndpoint disease="Herpesvirus infection" id="16795">HIV viral load</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Herpesvirus infection" id="16827"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Herpesvirus infection" id="16837"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lymphoma" id="3464"><Criterion>Subjects with B Cell Non Hodgkin's Lymphoma</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3465"><Criterion>Subjects with T Cell Non Hodgkin's Lymphoma</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3509"><Criterion>Subjects co-morbid with malignancy/tumor</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3506">Subjects with HIV associated lymphoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3519"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3527">Subjects co-morbid with systemic infection</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3528"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3530">Subjects with life expectancy of two months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3536"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3537">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Lymphoma" id="3538">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Lymphoma" id="3539">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion><SubCriterion disease="Lymphoma" id="3542">Subjects with Karnofsky score of 50 or higher</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3548"><Criterion>Subjects Diagnosed Based on Histo-Pathological Examination</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3585"><Criterion>Subjects with History of Use of Non-chemotherapeutic Drugs</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3609"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3614"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3621"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3622">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Lymphoma" id="3642">Subjects with normal/acceptable hematological functions</SubCriterion></SubCriteria></Inclusion><Inclusion disease="HIV infection" id="5311"><Criterion>Subjects with Specific HIV Test Results</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6176">Subjects with positive HIV infection test</SubCriterion></SubCriteria></Inclusion><Inclusion disease="HIV infection" id="5328"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="5330">Subjects with normal/acceptable blood chemistry</SubCriterion><SubCriterion disease="HIV infection" id="5331">Subjects with normal/acceptable liver function tests</SubCriterion><SubCriterion disease="HIV infection" id="5332">Subjects with normal/acceptable renal function tests</SubCriterion></SubCriteria></Inclusion><Inclusion disease="HIV infection" id="5344"><Criterion>Subjects on Prior/Concurrent Antiretroviral Therapy</Criterion></Inclusion><Inclusion disease="HIV infection" id="5427"><Criterion>Subjects With HIV Related Malignancy</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="5429">Subjects with Hodgkin/non-Hodgkin's lymphoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="7083"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3561">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Lymphoma" id="3578">Subjects with history of anti-cancer radiotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Herpesvirus infection" id="15731"><Criterion>Subjects with Epstein-Barr Virus Infections</Criterion><SubCriteria><SubCriterion disease="Herpesvirus infection" id="15733">Subjects with lymphoma/lymphoproliferative disorders</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Herpesvirus infection" id="15743"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Herpesvirus infection" id="15742">Subjects co-morbid with HIV infection</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Herpesvirus infection" id="15761"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion><SubCriteria><SubCriterion disease="Herpesvirus infection" id="15763">Subjects with protocol specified liver function tests</SubCriterion><SubCriterion disease="Herpesvirus infection" id="15764">Subjects with protocol specified renal function tests</SubCriterion></SubCriteria></Inclusion><Inclusion disease="HIV infection" id="33383"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="5329">Subjects with normal/acceptable hematological functions</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Herpesvirus infection" id="33393"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Herpesvirus infection" id="15762">Subjects with normal/acceptable hematological functions</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="34012"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3628">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lymphoma" id="4692"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4702"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4742"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4756">Subjects with hypersensitivity/contraindication to any investigational agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="4761"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4769">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Lymphoma" id="4783">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="4810"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="HIV infection" id="6820"><Criterion>Subjects with Opportunistic/Other Infections</Criterion></Exclusion><Exclusion disease="HIV infection" id="6824"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6825">Subjects co-morbid with ischemic heart disease</SubCriterion><SubCriterion disease="HIV infection" id="6826">Subjects co-morbid with congestive heart failure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="HIV infection" id="6834"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="HIV infection" id="6843"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6845">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="HIV infection" id="6859"><Criterion>Pregnant or Breast Feeding Subjects</Criterion></Exclusion><Exclusion disease="HIV infection" id="6866"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6941">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="HIV infection" id="6892"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="HIV infection" id="6938"><Criterion>Subjects co-morbid with Arrhythmias/Conduction Disorders</Criterion></Exclusion><Exclusion disease="Herpesvirus infection" id="13515"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Herpesvirus infection" id="13516"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Herpesvirus infection" id="13518"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Herpesvirus infection" id="13520"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Herpesvirus infection" id="13524"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Herpesvirus infection" id="13526">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Herpesvirus infection" id="13528"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Herpesvirus infection" id="13537"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Herpesvirus infection" id="13544"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="HIV infection" id="25989"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6833">Subjects co-morbid with peripheral neuropathy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="26332"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4739">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="26917"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4808">Subjects co-morbid with peripheral neuropathy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2014-10-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2014-10-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>83.06 Months</EnrollmentPeriod><EnrollmentRate>0.28 Patients/Month</EnrollmentRate><DateFirstReceived>2008-01-09T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-04-02T07:47:15Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-11-03T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2015-05-13T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-03-07T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="Added"><Date>2017-03-07T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-03-07T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-03-07T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-03-07T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-03-07T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-03-07T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-03-07T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-03-07T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-03-07T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-03-07T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-03-07T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-03-07T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-03-07T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change></ChangeHistory></Trial><Trial id="89255"><TitleDisplay>Pre-operative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases</TitleDisplay><TitleOfficial>Randomized, Phase II Trial of Pre-operative Chemoradiation With or Without Induction Chemotherapy In Patients With Locally Advanced Or Borderlinely Resectable Rectal Cancer With Resectable Synchronous Liver Metastases</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">XELOX-RT</Identifier><Identifier type="NCT">NCT01643070</Identifier></Identifiers><Indications><Indication id="1055">Rectal tumor</Indication><Indication id="202">Liver tumor</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>radiotherapy (5040 cGy)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>capecitabine</Name><Drug id="12205">capecitabine</Drug></Intervention><Intervention type="InterventionPrimary"><Name>oxaliplatin</Name><Drug id="3792">oxaliplatin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="12205">capecitabine</Drug><IndicationsPioneer/><Companies><Company><Company id="1036320">Asan Medical Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3792">oxaliplatin</Drug><IndicationsPioneer/><Companies><Company><Company id="1036320">Asan Medical Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3792" type="Drug"><TargetEntity id="108094" type="siDrug">Oxaliplatin</TargetEntity></SourceEntity><SourceEntity id="12205" type="Drug"><TargetEntity id="211639" type="siDrug">Capecitabine</TargetEntity></SourceEntity><SourceEntity id="1036320" type="Company"><TargetEntity id="5035525589" type="organizationId">Asan Medical Center</TargetEntity></SourceEntity><SourceEntity id="1055" type="ciIndication"><TargetEntity id="C20" type="ICD10"/><TargetEntity id="154.1" type="ICD9"/><TargetEntity id="10038038" type="MEDDRA"/><TargetEntity id="D012004" type="MeSH"/><TargetEntity id="-796050081" type="omicsDisease"/><TargetEntity id="640" type="siCondition"/></SourceEntity><SourceEntity id="202" type="ciIndication"><TargetEntity id="C22" type="ICD10"/><TargetEntity id="10019695" type="MEDDRA"/><TargetEntity id="D008113" type="MeSH"/><TargetEntity id="-897418746" type="omicsDisease"/><TargetEntity id="610" type="siCondition"/></SourceEntity><SourceEntity id="372" type="Action"><TargetEntity id="505" type="Mechanism">Thymidylate Synthase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1036320">Asan Medical Center</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="372">Thymidylate synthase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="140">DNA synthesis inhibitor</Class><Class id="1545">Anticancer</Class><Class id="1569">Anticancer antimetabolite</Class><Class id="50">Anticancer alkylating agent</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="1652">Prodrug</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Factorial Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>38</PatientCountEnrollment><PatientCountEvaluable>38</PatientCountEvaluable><DateStart>2010-01-31T00:00:00Z</DateStart><DateEnd type="estimated">2016-12-31T00:00:00Z</DateEnd><DateChangeLast>2016-12-26T05:33:35Z</DateChangeLast><DateAdded>2012-07-24T09:41:23Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Histologically confirmed adenocarcinoma of the rectum tumor located within 12 cm from             anal verge clinical stage of T3-4 or N+ by rectal MRI +/- endorectal ultrasound age             &gt; 18 years&lt;/li&gt;&lt;li&gt;No prior systemic treatment or radiation&lt;/li&gt;&lt;li&gt;Adequate major organ functions&lt;/li&gt;&lt;li&gt;Borderline resectability of primary rectal cancer complete resectability of liver             metastases (measurable by RECIST 1.1)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Unresectable liver metastases (six or more metastatic lesions, major vessel invasion)&lt;/li&gt;&lt;li&gt;Extrahepatic metastasis&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>R0 resection rate after simultaneous surgery of the rectum and the liver</Description><Timeframe>1 day</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this randomized, phase II study was to investigate the feasibility of pre-operative chemoradiation with &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt; plus      &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt;, with or without prior induction chemotherapy in patients with locally advanced      or marginally resectable rectal cancer with resectable synchronous liver metastases.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In December 2016, results were published. The overall R0 resection rate for both the primary tumor and LMs was found to be 77.8 and 70.0% in arms A and  B (p = 0.72), respectively. The median progression-free survival was found to be 14.2 versus 15.1 months (p = 0.422) and the three-year overall survival rate was observed 75.0 versus 88.8% (p = 0.29), respectively [&lt;ulink linkType="Reference" linkID="1887720"&gt;1887720&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive pre-operative chemoradiation      with &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt; (50 mg/m2/day on weekly) plus &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt; (825 mg/m2 po bid during radiotherapy [5040 cGy with 28 fractions]), with or without prior induction chemotherapy (&lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt; [1250 mg/m2 po bid on days 1 to 14] and &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt; [130 mg/m2 on day 1, q3w for two cycles]). &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were randomly assigned to receive either preoperative treatments of induction capecitabine and oxaliplatin (CapeOx), followed by chemoradiotherapy with CapeOx (CapeOx-RT) (arm A) or CapeOx-RT alone (arm B). Induction CapeOx consisted of oxaliplatin 130 mg/m2 on day 1 and capecitabine 1000 mg/m2 bid on days 1 to 14, q3w for two cycles; CapeOx-RT consisted of radiotherapy with 45 Gy/25 daily fractions, oxaliplatin 50 mg/m2 weekly for 5 weeks, and capecitabine 825 mg/m2 bid on days 1 to 38. Total mesorectal excision and simultaneous liver metastasectomy were planned within 6 weeks after completion of preoperative treatments [&lt;ulink linkType="Reference" linkID="1887720"&gt;1887720&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="222523">capecitabine</Intervention><Treatments><Treatment><Dose>825 milligram/m2</Dose><Route>Oral</Route></Treatment><Treatment><Dose>1000 milligram/m2</Dose><Route></Route></Treatment><Treatment><Dose>1250 milligram/m2</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="222524">oxaliplatin</Intervention><Treatments><Treatment><Dose>50 milligram/m2</Dose><Route></Route></Treatment><Treatment><Dose>130 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="South Korea"><Sites><Site><Name>Asan Medical Center</Name><Address1>Seoul</Address1><Address2>Songpa</Address2><Address3>138736</Address3><CountrySubDivision>Songpa</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Colorectal tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3813">Subjects with Rectal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3823">Subjects with TNM stage III/Dukes C Colorectal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3824">Subjects with TNM  stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01643070</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Colorectal tumor" id="8440"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8447">Assessment of tumor resectability</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Colorectal tumor" id="4467"><Criterion>Subjects with Rectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4482"><Criterion>Subjects with TNM Stage III/Dukes C Colorectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4483"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4509"><Criterion>Subjects with Histologically Confirmed Colorectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4517"><Criterion>Subjects with Resectable Colorectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4563"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Colorectal tumor" id="5825"><Criterion>Subjects with Metastatic Colorectal Cancer</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5928"><Criterion>Subjects with History of/Scheduled to Receive Colorectal Cancer Therapy</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5949"><Criterion>Subjects with history of/scheduled to receive radiation therapy</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="26377"><Criterion>Subjects by disease severity</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="20306">Subjects with Unresectable Colorectal Cancer</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2014-09-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2014-07-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>54.03 Months</EnrollmentPeriod><EnrollmentRate>0.70 Patients/Month</EnrollmentRate><DateFirstReceived>2011-11-01T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-07-24T09:41:23Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-07-22T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2016-12-26T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="89745"><TitleDisplay>A Study of LY-3023414 in Participants With Advanced Cancer</TitleDisplay><TitleOfficial>A Phase I, First-in-Human Dose Study of LY-3023414 in Patients With Advanced Cancer</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">13517</Identifier><Identifier type="NCT">NCT01655225</Identifier><Identifier type="Secondary Organisational">I6A-MC-CBBA</Identifier></Identifiers><Indications><Indication id="1240">Mesothelioma</Indication><Indication id="203">Lymphoma</Indication><Indication id="307">Squamous cell carcinoma</Indication><Indication id="319">Non-Hodgkin lymphoma</Indication><Indication id="3657">Metastatic breast cancer</Indication><Indication id="3665">Metastatic non small cell lung cancer</Indication><Indication id="3713">Advanced solid tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="3" role="Disease marker" type="Genomic;Proteomic">HER2</BiomarkerName><BiomarkerName id="10" role="Disease marker" type="Genomic;Proteomic">Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN</BiomarkerName><BiomarkerName id="213" role="Toxic effect marker" type="Biochemical">Creatinine</BiomarkerName><BiomarkerName id="1211" role="Toxic effect marker" type="Genomic;Proteomic">Alanine transaminase</BiomarkerName><BiomarkerName id="3196" role="Disease marker" type="Genomic;Proteomic">Phosphatidylinositol 3-kinase regulatory subunit alpha</BiomarkerName><BiomarkerName id="8458" role="Toxic effect marker" type="Genomic;Proteomic">gamma-Glutamyltransferase</BiomarkerName><BiomarkerName id="12058" role="Toxic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>samotolisib</Name><Drug id="79933">samotolisib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>LY-3023414 + fulvestrant</Name></Intervention><Intervention type="InterventionPrimary"><Name>abemaciclib</Name><Drug id="72538">abemaciclib</Drug></Intervention><Intervention type="InterventionPrimary"><Name>cisplatin</Name></Intervention><Intervention type="InterventionPrimary"><Name>fulvestrant</Name><Drug id="3313">fulvestrant</Drug></Intervention><Intervention type="InterventionPrimary"><Name>letrozole</Name><Drug id="2784">letrozole</Drug></Intervention><Intervention type="InterventionPrimary"><Name>midazolam hydrochloride</Name><Drug id="44303">midazolam hydrochloride</Drug></Intervention><Intervention type="InterventionPrimary"><Name>pemetrexed disodium</Name><Drug id="3536">pemetrexed disodium</Drug></Intervention><Intervention type="InterventionPrimary"><Name>samotolisib</Name><Drug id="79933">samotolisib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2784">letrozole</Drug><IndicationsPioneer><Indication id="1240">Mesothelioma</Indication><Indication id="203">Lymphoma</Indication><Indication id="307">Squamous cell carcinoma</Indication></IndicationsPioneer><Companies><Company><Company id="17810">Eli Lilly &amp; Co</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3313">fulvestrant</Drug><IndicationsPioneer><Indication id="1240">Mesothelioma</Indication><Indication id="203">Lymphoma</Indication><Indication id="307">Squamous cell carcinoma</Indication></IndicationsPioneer><Companies><Company><Company id="17810">Eli Lilly &amp; Co</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3536">pemetrexed disodium</Drug><IndicationsPioneer/><Companies><Company><Company id="17810">Eli Lilly &amp; Co</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44303">midazolam hydrochloride</Drug><IndicationsPioneer><Indication id="1240">Mesothelioma</Indication><Indication id="3665">Metastatic non small cell lung cancer</Indication></IndicationsPioneer><Companies><Company><Company id="17810">Eli Lilly &amp; Co</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="72538">abemaciclib</Drug><IndicationsPioneer><Indication id="1240">Mesothelioma</Indication><Indication id="203">Lymphoma</Indication><Indication id="307">Squamous cell carcinoma</Indication><Indication id="319">Non-Hodgkin lymphoma</Indication><Indication id="3713">Advanced solid tumor</Indication></IndicationsPioneer><Companies><Company><Company id="17810">Eli Lilly &amp; Co</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="79933">samotolisib</Drug><IndicationsPioneer><Indication id="1240">Mesothelioma</Indication><Indication id="203">Lymphoma</Indication><Indication id="307">Squamous cell carcinoma</Indication><Indication id="319">Non-Hodgkin lymphoma</Indication><Indication id="3657">Metastatic breast cancer</Indication><Indication id="3665">Metastatic non small cell lung cancer</Indication><Indication id="3713">Advanced solid tumor</Indication></IndicationsPioneer><Companies><Company><Company id="17810">Eli Lilly &amp; Co</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="79933">samotolisib</Drug><IndicationsPioneer><Indication id="1240">Mesothelioma</Indication><Indication id="203">Lymphoma</Indication><Indication id="307">Squamous cell carcinoma</Indication><Indication id="319">Non-Hodgkin lymphoma</Indication><Indication id="3657">Metastatic breast cancer</Indication><Indication id="3665">Metastatic non small cell lung cancer</Indication><Indication id="3713">Advanced solid tumor</Indication></IndicationsPioneer><Companies><Company><Company id="17810">Eli Lilly &amp; Co</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2784" type="Drug"><TargetEntity id="164958" type="siDrug">Letrozole</TargetEntity></SourceEntity><SourceEntity id="3536" type="Drug"><TargetEntity id="173565" type="siDrug">Pemetrexed disodium</TargetEntity></SourceEntity><SourceEntity id="3313" type="Drug"><TargetEntity id="177872" type="siDrug">Fulvestrant</TargetEntity></SourceEntity><SourceEntity id="72538" type="Drug"><TargetEntity id="746802" type="siDrug">Abemaciclib mesylate</TargetEntity></SourceEntity><SourceEntity id="79933" type="Drug"><TargetEntity id="784278" type="siDrug"></TargetEntity><TargetEntity id="784278" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="44303" type="Drug"><TargetEntity id="91131" type="siDrug">Midazolam maleate</TargetEntity></SourceEntity><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="1240" type="ciIndication"><TargetEntity id="C45" type="ICD10"/><TargetEntity id="163" type="ICD9"/><TargetEntity id="10027406" type="MEDDRA"/><TargetEntity id="D008654" type="MeSH"/><TargetEntity id="50251" type="ORPHANET"/><TargetEntity id="-666440137" type="omicsDisease"/><TargetEntity id="2015" type="siCondition"/></SourceEntity><SourceEntity id="203" type="ciIndication"><TargetEntity id="10025310" type="MEDDRA"/><TargetEntity id="D008223" type="MeSH"/><TargetEntity id="-386134440" type="omicsDisease"/><TargetEntity id="698" type="siCondition"/></SourceEntity><SourceEntity id="307" type="ciIndication"><TargetEntity id="10041823" type="MEDDRA"/><TargetEntity id="D002294" type="MeSH"/><TargetEntity id="-1612557995" type="omicsDisease"/><TargetEntity id="676" type="siCondition"/></SourceEntity><SourceEntity id="319" type="ciIndication"><TargetEntity id="10029547" type="MEDDRA"/><TargetEntity id="D008228" type="MeSH"/><TargetEntity id="547" type="ORPHANET"/><TargetEntity id="-1008757452" type="omicsDisease"/><TargetEntity id="703" type="siCondition"/></SourceEntity><SourceEntity id="3657" type="ciIndication"><TargetEntity id="10055113" type="MEDDRA"/><TargetEntity id="589" type="siCondition"/></SourceEntity><SourceEntity id="3665" type="ciIndication"><TargetEntity id="10059515" type="MEDDRA"/><TargetEntity id="613" type="siCondition"/></SourceEntity><SourceEntity id="10240" type="Action"><TargetEntity id="1705" type="Mechanism">Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="135" type="Action"><TargetEntity id="413" type="Mechanism">Dihydrofolate Reductase (DHFR) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1575" type="Action"><TargetEntity id="465" type="Mechanism">Phosphatidylinositol 3-Kinase (PI3K) Inhibitors</TargetEntity><TargetEntity id="3512" type="Mechanism">Inositol Phosphate Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="181" type="Action"><TargetEntity id="432" type="Mechanism">Glycinamide Ribonucleotide Formyltransferase (GARTFase) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="286" type="Action"><TargetEntity id="1284" type="Mechanism">Estrogen Receptor (ER) Antagonists</TargetEntity><TargetEntity id="3050" type="Mechanism">Selective Estrogen Receptor Destabilizers (SERD)</TargetEntity><TargetEntity id="3127" type="Mechanism">Estrogen Receptor (ER) Zinc Finger Inhibitors</TargetEntity></SourceEntity><SourceEntity id="372" type="Action"><TargetEntity id="505" type="Mechanism">Thymidylate Synthase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4314" type="Action"><TargetEntity id="984" type="Mechanism">CDK4 Inhibitors</TargetEntity><TargetEntity id="1721" type="Mechanism">CDK4/Cyclin D1 Inhibitors</TargetEntity><TargetEntity id="3006" type="Mechanism">CDK4/Cyclin D3 Inhibitors</TargetEntity><TargetEntity id="3181" type="Mechanism">CDK4/Cyclin D Inhibitors</TargetEntity><TargetEntity id="3182" type="Mechanism">CDK4/Cyclin D2 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4318" type="Action"><TargetEntity id="1234" type="Mechanism">CDK6 Inhibitors</TargetEntity><TargetEntity id="2255" type="Mechanism">CDK6/Cyclin D3 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4528" type="Action"><TargetEntity id="3101" type="Mechanism">Pim-1 Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="76" type="Action"><TargetEntity id="393" type="Mechanism">Aromatase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="81" type="Action"><TargetEntity id="191" type="Mechanism">GABA(A) BZ Site Receptor Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>8</NumberOfSites><CompaniesSponsor><Company id="17810">Eli Lilly &amp; Co</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="10240">mTOR inhibitor</Action><Action id="135">DHFR inhibitor</Action><Action id="1575">Phosphoinositide 3-kinase inhibitor</Action><Action id="181">GAR transformylase inhibitor</Action><Action id="286">Estrogen receptor antagonist</Action><Action id="372">Thymidylate synthase inhibitor</Action><Action id="374">Transferase inhibitor</Action><Action id="4314">Cyclin-dependent kinase-4 inhibitor</Action><Action id="4318">Cyclin-dependent kinase-6 inhibitor</Action><Action id="4528">PIM-1 protein kinase inhibitor</Action><Action id="76">Aromatase inhibitor</Action><Action id="81">Benzodiazepine receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1569">Anticancer antimetabolite</Class><Class id="1589">Apoptosis stimulator</Class><Class id="1668">General anesthetic</Class><Class id="2942">Anxiolytic</Class><Class id="62254">Anticancer hormone antagonist</Class><Class id="62255">Anticancer protein kinase inhibitor</Class><Class id="7293">Synergist</Class><Class id="767">Cell cycle inhibitor</Class><Class id="805">Folate modulator</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="751">Film coating</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="740">Infusion</Technology><Technology id="596">Injectable formulation</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="589">Sustained release formulation</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>156</PatientCountEnrollment><PatientCountEvaluable>9</PatientCountEvaluable><DateStart>2012-07-31T00:00:00Z</DateStart><DateEnd type="estimated">2020-03-13T00:00:00Z</DateEnd><DateChangeLast>2019-06-19T02:07:30Z</DateChangeLast><DateAdded>2012-08-02T04:31:03Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>UCLA Medical Center</Affiliation><Name>Parvin Peddi</Name><Phone>310-325-8252</Phone></Contact><Contact type="Public contact"><Affiliation>Memorial Sloan Kettering Cancer Center</Affiliation><Name>Anna Varghese</Name><Phone>646-888-4226</Phone></Contact><Contact type="Public contact"><Affiliation>Peggy and Charles Stephenson Oklahoma Cancer Center</Affiliation><Name>Raid Aljumaily</Name><Phone>405-271-8777</Phone></Contact><Contact type="Public contact"><Affiliation>Penn Presbyterian Medical Center</Affiliation><Name>Evan Alley</Name><Phone>800-789-7366</Phone></Contact><Contact type="Public contact"><Affiliation>SMO Sarah Cannon Research Inst.</Affiliation><Name>Sarah Cannon Research Inst.</Name></Contact><Contact type="Public contact"><Affiliation>Tennessee Oncology PLLC</Affiliation><Name>Johanna Bendell</Name><Phone>615-329-7274</Phone></Contact><Contact type="Public contact"><Affiliation>Fundacion de Investigacion de Diego</Affiliation><Name>Mirelis Acosta-Rivera</Name><Phone>7877221248</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Parts A, A2 and B1: participants must have pathological evidence of a diagnosis of advanced and/or metastatic cancer and must be, in the judgment of the investigator, an appropriate candidate for experimental therapy&lt;/li&gt;&lt;li&gt;Part B2: participants must have advanced, recurrent, or metastatic breast cancer that is refractory to aromatase inhibitors (AI) with either disease recurrence or disease progression; must be hormone receptor positive (HR+) and human epidermal growth factor receptor 2 (HER2)-negative; must be of postmenopausal status or beginning ovarian suppression with a luteinizing hormone-releasing hormone (LHRH) agonist&lt;/li&gt;&lt;li&gt;Part B3 only: participants must have malignant pleural or peritoneal mesothelioma&lt;/li&gt;&lt;li&gt;Part B4 only: participants must have malignant pleural or peritoneal mesothelioma and appropriate candidate for treatment with cisplatin/pemetrexed; no prior systemic chemotherapy&lt;/li&gt;&lt;li&gt;Part B5 only: participants must have histologically confirmed diagnosis of B-cell iNHL, with histological subtype; prior treatment with &gt;/= 2 prior chemotherapy- or immunotherapy-based regimens for iNHL&lt;/li&gt;&lt;li&gt;Part B6 only: participants must have squamous NSCLC; documented evidence of an activating molecular aberration of the PI3K/mTOR pathway&lt;/li&gt;&lt;li&gt;Parts B2, B3  and B6 only: must have adequate tumor tissue sample from archival biopsy available, or willingness to undergo a fresh tumor biopsy&lt;/li&gt;&lt;li&gt;Parts B3, B4, B5 and; B6: no previous treatment with any PI3K and/or mTOR inhibitor&lt;/li&gt;&lt;li&gt;Part B7: Must have a diagnosis of HR+ and HER2- breast cancer; have locoregionally recurrent disease not amenable to resection or radiation therapy with curative intent or metastatic disease; no previous treatment or currently receiving 1 of the following treatments for locoregionally recurrent or metastatic breast cancer (chemotherapy, endocrine therapy, CDK4/6 inhibitor, and PI3K and/or mTOR inhibitor)&lt;/li&gt;&lt;li&gt;Measurable or nonmeasurable disease as defined by the Response Evaluation Criteria in             Solid Tumors (RECIST Version 1.1) or Revised Response Criteria for Malignant Lymphoma&lt;/li&gt;&lt;li&gt;Have adequate organ function, including:&lt;ul&gt;&lt;li&gt;Absolute neutrophil count (ANC) at least 1.5             x 10(9)/l&lt;/li&gt;&lt;li&gt;Platelets at least 100 x 10(9)/l&lt;/li&gt;&lt;li&gt;Hemoglobin at least 8              g/dl&lt;/li&gt;&lt;li&gt;Bilirubin no more than 1.5 x upper limits of normal (ULN)&lt;/li&gt;&lt;li&gt;Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) no more than 2.0             x ULN&lt;/li&gt;&lt;li&gt;Serum creatinine no more than 1.5 x ULN or calculated creatinine clearance&amp;gt; 45  ml/min)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Have a performance status of at least  1 on the Eastern Cooperative Oncology Group             (ECOG) scale and life expectancy&amp;gt; 6 months&lt;/li&gt;&lt;li&gt;Have discontinued all previous cancer therapies (except nonsteroidal aromatase             inhibitors for participants in Part B2), and any agents that have not received             regulatory approval for any indication, for at least 21 days or five half lives prior to             study enrollment, whichever is shorter, and recovered from the acute effects of             therapy. Participants must have discontinued mitomycin-C or nitrosourea therapy for             at least 42 days&lt;/li&gt;&lt;li&gt;Are able to swallow capsules&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Have serious preexisting medical conditions&lt;/li&gt;&lt;li&gt;Have symptomatic central nervous system (CNS) malignancy (with the exception of             medulloblastoma) or metastasis (screening not required).  Participants with treated             CNS metastases are eligible for this study if they are not currently receiving             corticosteroids and/or anticonvulsants, and their disease is asymptomatic and             radiographically stable for at least 60 days (screening not required)&lt;/li&gt;&lt;li&gt;Have known acute or chronic leukemia or current hematological malignancies that, in the             judgment of the investigator and sponsor, may affect the interpretation of results&lt;/li&gt;&lt;li&gt;Have an active fungal, bacterial, and/or known viral infection, including:  human             immunodeficiency virus (HIV), or hepatitis A, B or C.  Hepatocellular cancer (HCC)             participants with chronic viral (B or C) hepatitis are eligible if they retain             adequate liver function per Child-Pugh Stage A&lt;/li&gt;&lt;li&gt;Have a second primary malignancy that in the judgment of the investigator and sponsor             may affect the interpretation of results (Part B only)&lt;/li&gt;&lt;li&gt;Part B1 only:  No concomitant medications that are strong inhibitors or inducers of             cytochrome P450 3A4 (CYP3A4) or midazolam&lt;/li&gt;&lt;li&gt;Intolerance to any previous treatment with any phosphatidylinositol-3-kinase (PI3K)             and/or mammalian target of rapamycin (mTOR) inhibitor. Treatment with any PI3K and/or             mTOR inhibitor must have discontinued at least five half-lives prior to study enrollment             and participants must have recovered from the acute effects of therapy             (treatment-related toxicity resolved to baseline or less than Grade 1).  In Part B,             no previous treatment with any PI3K and/or mTOR inhibitor is allowed&lt;/li&gt;&lt;li&gt;Participants with active alcohol abuse, as determined by the investigator&lt;/li&gt;&lt;li&gt;Have a history of New York Heart Association (NYHA) Class &gt;/= 3, unstable angina, or             myocardial infarction (MI) in 6 months prior to study drug administration&lt;/li&gt;&lt;li&gt;Have QT interval corrected using Fridericia's formula (QTcF) of&amp;gt; 450 ms  on screening electrocardiogram (ECG)&lt;/li&gt;&lt;li&gt;Have insulin-dependent diabetes mellitus or a history of gestational diabetes             mellitus.  Participants with a type 2 diabetes mellitus are eligible if adequate             control of blood glucose level is obtained by oral anti-diabetics as documented by             hemoglobin A1c &amp;lt; 7%&lt;/li&gt;&lt;li&gt;Part B only: hypersensitivity to study drugs given in combination with LY-3023414&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Recommended phase II dose</Description><Timeframe>Baseline to disease progression or participant discontinuation (estimated 9 weeks)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Pharmacokinetics: maximum concentration (Cmax)</Description><Timeframe>Predose up to 12 h postdose</Timeframe></Measure><Measure><Description>Pharmacokinetics: time of maximal concentration</Description><Timeframe>Predose up to 12 h postdose</Timeframe></Measure><Measure><Description>Number of participants with tumor response</Description><Timeframe>Baseline to disease progression or participant discontinuation (estimated 9 weeks)</Timeframe></Measure><Measure><Description>Potential of LY-3023414 to inhibit CYP3A4-mediated metabolism</Description><Timeframe>Baseline to cycle 1</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In June 2017, results were presented.  A total of seven participants discontinued study due to progressive disease, investigator decision, participant decision and adverse event (AE). AEs occurring in &amp;gt; 1 participant were nausea (56%), vomiting (44%), oral mucositis (44%), fatigue (33%), decreased appetite (33%), mucosal inflammation (22%) and paresthesia (22%). Most of the AEs were mild or moderate in severity. In cycle 1, two participants reported DLT (Grade 3 oral mucositis). Grade 4 or 5 treatment-emergent AEs were not reported [&lt;ulink linkType="Reference" linkID="1932099"&gt;1932099&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2018, results were presented. Reasons for discontinuation were progressive disease, adverse event, participant decision, investigator decision, and death reported in 51, 7, 12, 17, and 12% of participants, respectively. A 42% of participants had dose adjustments. Any grade, grade &gt;/= 3, SAE, discontinued due to AE and SAE, died while on therapy, and died within 30 days of treatment discontinuation were reported in 98, 44, 51, 10, 7, 7, and 5% of participants with TEAE, and 90, 20, 17, 5, 2, 0, and 0% of participants with TRAE, respectively. SAE related to study treatment were hyperglycemia, mucosal inflammation, pneumonitis, cardiac failure, fatigue, dyspnea, and dyspnea exertional were reported in 5, 2, 2, 2, 7, 5, and 2% of participants with any grades, and 5, 0, 0, 0, 2, 0, and 2% of participants with grade &gt;/= 3. Treatment-related adverse events observed in &gt;/= 2 patients and all grade &gt;/= 3 events were reported. Nausea, vomiting, diarrhea, stomatitis, gastroesophageal reflux disease, paraesthesia oral, fatigue, mucosal inflammation, increased blood creatinine, decreased weight, increased ALT, GGT, decreased appetite, hyperglycemia, hyponatremia, dizziness, dysgeusia, paraesthesia, acute kidney injury, dyspnea, macula-papular rash, pruritus, and dry skin were reported in 37, 34, 22, 10, 5, 5, 44, 10, 10, 7, 5, 5,29, 5, 5, 5, 5, 5, 5, 5, 15, 10, and 7% of participants, respectively. TRAE including constipation, fatigue, hyperglycemia, hyponatremia, dizziness, dysgeusia, exertional, hypoxia, macula-papular rash, and pruritus were reported in 2, 10, 5, 2, 2, 2, 7, and 5% of participants with all grade &gt;/= 3, respectively [&lt;ulink linkType="Reference" linkID="2022168"&gt;2022168&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2018, results were published. Dose-limiting toxicities were observed at 450 mg qd (n = 3/3) (thrombocytopenia, hypotension, hyperkalemia), 250 mg, bid (n = 3/4) (hypophosphatemia, fatigue, mucositis) and 200 mg bid (n = 1/15) (nausea). Common related AEs included nausea, fatigue and vomiting (38, 34 and 32% of patients, respectively) and were mostly mild or moderate [&lt;ulink linkType="Reference" linkID="2071174"&gt;2071174&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to find a recommended dose level and schedule of dosing      &lt;ulink linkType="Drug" linkID="79933"&gt;LY-3023414&lt;/ulink&gt; that can safely be taken by participants with advanced or metastatic cancer,      including but not limited to lymphoma, breast cancer, and mesothelioma. The study would  also      explore the changes to various markers in blood cells and potentially tumor cells. Finally,      the study would help document any antitumor activity this drug may have.&lt;/para&gt;&lt;para&gt;Objectives:&lt;br/&gt;Primary: determine rapid phase II dose and schedule of adminstration.&lt;br/&gt;Secondary: safety and toxicity, PK/pharmacodynamics, antitumor activity.&lt;br/&gt;Exploratory: biomarker analysis [&lt;ulink linkType="Reference" linkID="2022168"&gt;2022168&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2071174"&gt;2071174&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In June 2017, results were presented. Of nine participants, partial response was achieved by one participant, stable disease was observed in four patients, and progressive disease was observed in one patient; overall response rate was 11%, and disease control rate was 56%. Median progression-free survival was 4.2 months. With LY-3023414 alone and in combination with fulvestrant (n = 44 and 4, respectively), AUC at steady state was 2940 and 4420 ng.h/ml, respectively; and Cmin at steady state was 19.1 and 25.2 ng/ml, respectively. With fulvestrant alone and in combination with LY-3023414 (n = 3), respectively), AUC at steady state was 13100 and 10990 ng.h/ml, respectively; and Cmin at steady state was 12.2 and 11.8 ng/ml, respectively. These results indicated no obvious impact of LY-3023414 on fulvestrant pharmacokinetics and vice versa [&lt;ulink linkType="Reference" linkID="1932099"&gt;1932099&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2018, results were presented. The objective response rate (CR + PR), disease control rate (CR + PR + SD), CR, PR, SD and PD were reported in 5, 46, 0, 5, 42, and 22% of participants, respectively. Median duration of therapy was 12 weeks and relative dose intensity was in 86% of participants [&lt;ulink linkType="Reference" linkID="2022168"&gt;2022168&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2018, results were published. LY-3023414 pharmacokinetics demonstrated dose-dependent increase in exposure with &gt;/= 90% target inhibition at doses &gt;/= 150 mg. DDI analysis showed that LY-3023414 was a weak inhibitor of CYP-3A4. Durable partial response was observed in a participant with endometrial cancer harboring PIK3R1 and PTEN truncating mutations, and 13 additional participants (28%) had a decrease in their target lesions by up to 30% [&lt;ulink linkType="Reference" linkID="2071174"&gt;2071174&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;There  would be five arms in this study.  In Part A of this study, participants with advanced/metastatic cancer (including lymphoma)      would receive increasing doses of &lt;ulink linkType="Drug" linkID="79933"/&gt;LY-3023414.  In Part B, LY-3023414  would be explored in      different types of cancer, including breast cancer and mesothelioma.&lt;br/&gt;Arm 1 (Part A): &lt;ulink linkType="Drug" linkID="79933"/&gt;LY-3023414 (20 to 600 mg) would be administered po qd  at escalating doses for two 21-day cycles  to participants with advanced  cancer (including lymphoma); participants receiving benefit may continue until disease progression or discontinuation.&lt;br/&gt;Arm 2 (Part A2): LY-3023414 would be administered po bid  at escalating doses for two 21-day cycles to participants with advanced  cancer (including lymphoma); participants receiving benefit may continue until disease progression or discontinuation.&lt;br/&gt;Arm 3 (Part B1): &lt;ulink linkType="Drug" linkID="79933"/&gt;LY-3023414 would be administered po  bid for two 21-day cycles to participants with advanced  cancer; participants receiving benefit may continue until disease progression or discontinuation. Dose will be based on Part A.  &lt;ulink linkType="Drug" linkID="44303"&gt;Midazolam&lt;/ulink&gt; 0.2 mg po would be  administered   once before &lt;ulink linkType="Drug" linkID="79933"/&gt;LY-3023414 on day 1 and once after LY-3023414 on day 15.&lt;br/&gt;Arm 4 (Part B2): LY-3023414 would be administered po  bid for two 21-day cycles to participants with advanced  breast cancer; participants receiving benefit may continue until disease progression or discontinuation. Dose would be based on Part A.  &lt;ulink linkType="Drug" linkID="2784"/&gt;500 mg &lt;ulink linkType="Drug" linkID="3313"&gt;fulvestrant&lt;/ulink&gt; administered im q28d.&lt;br/&gt;Arm 5 (Part B3): &lt;ulink linkType="Drug" linkID="79933"/&gt;LY-3023414 would be  administered po bid for two 21-day cycles to participants with malignant mesothelioma; participants receiving benefit may continue until disease progression or discontinuation. Dose would be based on Part A.&lt;br/&gt;Arm  6: Part B4: Abemaciclib + &lt;ulink linkType="Drug" linkID="3536"&gt;pemetrexed&lt;/ulink&gt;/cisplatin: LY-3023414 administered po bid for two 21 day cycles to participants with malignant mesothelioma; participants receiving benefit may continue until disease progression or discontinuation. 500 mg/m2 pemetrexed and 75 mg/m2 cisplatin administered iv once q21d.&lt;br/&gt;Arm  7: Part B5: LY-3023414: LY-3023414 administered po bid for two 21 day cycles to participants with indolent non-Hodgkin's lymphoma; participants receiving benefit may continue until disease progression or discontinuation.&lt;br/&gt;Arm  8: Part B6: LY-3023414: LY-3023414 administered po bid for two 21 day cycles to participants with squamous NSCLC; participants receiving benefit may continue until disease progression or discontinuation.&lt;br/&gt;Arm  9: Part B7: LY-3023414 administered po bid + &lt;ulink linkType="Drug" linkID="72538"&gt;abemaciclib&lt;/ulink&gt; administered orally twice-daily + &lt;ulink linkType="Drug" linkID="2784"&gt;letrozole&lt;/ulink&gt; will be administered orally once a day for two 28 day cycles to participants with breast cancer; participants receiving benefit may continue until disease progression or discontinuation.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Participants (n = 9) received LY-3023414 (200 mg bid) + fulvestrant (500 mg on day 1 and 15 of cycle 1, then once monthly) [&lt;ulink linkType="Reference" linkID="1932099"&gt;1932099&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In mesothelioma expansion cohort, 41 participants received 200 mg, bid of LY-3023414 [&lt;ulink linkType="Reference" linkID="2022168"&gt;2022168&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Participants received LY-3023414, 20 to 450 mg, qd or 150 to 250 mg, bid [&lt;ulink linkType="Reference" linkID="2071174"&gt;2071174&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;br/&gt;&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>samotolisib</Name><Drug id="79933">samotolisib</Drug><Dose unit="milligram dose">200.0</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="1016">Stomatitis</Indication><CountPatientsAffectedPercentage>10.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="102">Diarrhea</Indication><CountPatientsAffectedPercentage>22.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="110">Emesis</Indication><CountPatientsAffectedPercentage>34.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="1243">Gastroesophageal reflux</Indication><CountPatientsAffectedPercentage>5.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="1256">Hyponatremia</Indication><CountPatientsAffectedPercentage>5.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="1821">Hyperglycemia</Indication><CountPatientsAffectedPercentage>5.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsAffectedPercentage>37.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="2400">Dyspnea</Indication><CountPatientsAffectedPercentage>5.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="2576">Dysgeusia</Indication><CountPatientsAffectedPercentage>5.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="279">Pruritus</Indication><CountPatientsAffectedPercentage>10.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3038">Appetite loss</Indication><CountPatientsAffectedPercentage>29.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3108">Renal injury</Indication><CountPatientsAffectedPercentage>5.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3454">Dizziness</Indication><CountPatientsAffectedPercentage>5.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3868">Xerosis</Indication><CountPatientsAffectedPercentage>7.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="829">Fatigue</Indication><CountPatientsAffectedPercentage>44.0</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>samotolisib</Name><Drug id="79933">samotolisib</Drug><Dose unit="milligram dose">250.0</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="1263">Mucositis</Indication></AdverseEvent><AdverseEvent><Indication id="1280">Hypophosphatemia</Indication></AdverseEvent><AdverseEvent><Indication id="829">Fatigue</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>samotolisib</Name><Drug id="79933">samotolisib</Drug><Dose unit="milligram dose">450.0</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="2738">Hyperkalemia</Indication></AdverseEvent><AdverseEvent><Indication id="324">Thrombocytopenia</Indication></AdverseEvent><AdverseEvent><Indication id="408">Hypotension</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>LY-3023414 + fulvestrant</Name><Dose unit="milligram dose">200.0</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="2469">Paresthesia</Indication><CountPatientsAffectedPercentage>22.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3038">Appetite loss</Indication><CountPatientsAffectedPercentage>33.0</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>LY-3023414 + fulvestrant</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="110">Emesis</Indication><CountPatientsAffectedPercentage>44.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsAffectedPercentage>56.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3209">Oral mucositis</Indication><CountPatientsAffectedPercentage>44.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="829">Fatigue</Indication><CountPatientsAffectedPercentage>33.0</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="557523">cisplatin</Intervention><Treatments><Treatment><Dose>75 milligram/m2</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="557521">fulvestrant</Intervention><Treatments><Treatment><Dose>500 milligram</Dose><Route>Intramuscular</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="223917">midazolam hydrochloride</Intervention><Treatments><Treatment><Dose>0.2 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="557522">pemetrexed disodium</Intervention><Treatments><Treatment><Dose>500 milligram/m2</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="223892">samotolisib</Intervention><Treatments><Treatment><Dose>20 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>150 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>200 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>250 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>450 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>600 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Italy"><Sites><Site><Name>Azienda Ospedaliero - Universitaria S. Luigi Gonzaga</Name><Address1>Orbassano</Address1><Address2>Torino</Address2><Address3>10043</Address3><CountrySubDivision>Torino</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Puerto Rico"><Sites><Site><Name>Fundacion de Investigacion de Diego</Name><Address1>San Juan</Address1><Address3>00927</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>Memorial Sloan Kettering Cancer Center</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10065</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>Peggy and Charles Stephenson Oklahoma Cancer Center</Name><Address1>Oklahoma City</Address1><Address2>Oklahoma</Address2><Address3>73104</Address3><CountrySubDivision code="OK">Oklahoma</CountrySubDivision><Contacts/></Site><Site><Name>Penn Presbyterian Medical Center</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><Address3>19104</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts/></Site><Site><Name>Sarah Cannon Cancer Center</Name><Address1>Nashville</Address1><Address2>Tennessee</Address2><Address3>37203</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts/></Site><Site><Name>Tennessee Oncology PLLC</Name><Address1>Nashville</Address1><Address2>Tennessee</Address2><Address3>37203</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts/></Site><Site><Name>UCLA Medical Center</Name><Address1>Los Angeles</Address1><Address2>California</Address2><Address3>90095</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Breast tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3954">Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3965">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Mesothelioma</Disease><PatientSegments><PatientSegment><PatientSegment id="8137">Subjects with Advanced Mesothelioma</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8145">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Lymphoma</Disease><PatientSegments><PatientSegment><PatientSegment id="7058">Lymphoma Subjects with Advanced Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Solid tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="7961">Subjects with Advanced/Metastatic Solid Tumors</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7967">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01655225</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Lymphoma" id="7775"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7776">Optimum/therapeutic/safe dose evaluation of drug</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Breast tumor" id="9122"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Mesothelioma" id="12529"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Solid tumor" id="15312"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Lymphoma" id="7604"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7608">Assessment of number of participants with response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Lymphoma" id="7775"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7779">Assessment of maximum concentration of drug (Cmax)</SubEndpoint><SubEndpoint disease="Lymphoma" id="7780">Time to maximum concentration (Tmax)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="8726"><Endpoint>Assessment of Response Rates (RR)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="9122"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Mesothelioma" id="12491"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Mesothelioma" id="12497">Assessment of tumor response rate</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Mesothelioma" id="12529"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15209"><Endpoint>Assessment of Disease Progression</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15211"><Endpoint>Assessment of Response Rates (RR)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15312"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lymphoma" id="3497"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3528"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3533">Subjects with life expectancy of six months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3536"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3538">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3548"><Criterion>Subjects Diagnosed Based on Histo-Pathological Examination</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3621"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3622">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Lymphoma" id="3642">Subjects with normal/acceptable hematological functions</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4840"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4856"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4857">Subjects with measurable disease as per RECIST criteria</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4877"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4878"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4880">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4922"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Inclusion><Inclusion disease="Lymphoma" id="5249"><Criterion>Lymphoma Subjects with Advanced Disease</Criterion></Inclusion><Inclusion disease="Mesothelioma" id="8536"><Criterion>Subjects with Advanced Mesothelioma</Criterion></Inclusion><Inclusion disease="Mesothelioma" id="8543"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Mesothelioma" id="8555"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="8557">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Mesothelioma" id="8573"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Inclusion><Inclusion disease="Mesothelioma" id="8574"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="8575">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Mesothelioma" id="8576">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="13096"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Solid tumor" id="13098"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13100">Subjects with disease measurable by imaging techniques</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="13109"><Criterion>Subjects with Protocol Specified Performance Status </Criterion></Inclusion><Inclusion disease="Solid tumor" id="13129"><Criterion>Subjects with Treatment Refractory Disease</Criterion></Inclusion><Inclusion disease="Solid tumor" id="13130"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13131">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Solid tumor" id="13132">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="14854"><Criterion>Subjects with Non-measurable Disease</Criterion></Inclusion><Inclusion disease="Lymphoma" id="34012"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3628">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="34030"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13133">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Mesothelioma" id="34042"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="8577">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lymphoma" id="4692"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4701">Subjects with other hematological malignancies</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="4702"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4742"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="12805">Subjects with hypersensitivity/contraindication to targeted therapy agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="4810"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6252"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6257"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6258"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6272"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6294"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6393"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Exclusion><Exclusion disease="Lymphoma" id="6765"><Criterion>Subjects with Primary Lymphoma</Criterion></Exclusion><Exclusion disease="Mesothelioma" id="10094"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Mesothelioma" id="10095"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Mesothelioma" id="10114"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="10116">Subjects with hypersensitivity/contraindication to targeted therapy agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Mesothelioma" id="10130"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Solid tumor" id="10704"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Solid tumor" id="10723"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10725">Subjects with hypersensitivity/contraindication to targeted therapy agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Solid tumor" id="10739"><Criterion>Subjects with History of Other Non Anti-cancer Drugs/Agents</Criterion></Exclusion><Exclusion disease="Solid tumor" id="12316"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Lymphoma" id="26332"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4739">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Mesothelioma" id="26346"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Mesothelioma" id="10108">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Solid tumor" id="26347"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10717">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="26375"><Criterion>Subjects by disease severity</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6247">Subjects with Brain/Leptomeningeal metastases</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2019-04-04T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2019-06-05T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>82.19 Months</EnrollmentPeriod><EnrollmentRate>1.90 Patients/Month</EnrollmentRate><DateFirstReceived>2012-07-19T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-08-02T04:31:03Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2017-09-28T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="Added"><Date>2017-09-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-09-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-09-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-09-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-09-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-09-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-05-30T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-05-30T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-05-30T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-05-30T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-05-30T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-05-30T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-05-30T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-05-30T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-05-30T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-05-30T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-05-30T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-05-30T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-05-30T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-05-30T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-05-30T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-09-13T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-09-13T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-09-13T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-09-13T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-09-13T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2018-09-13T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="updated"><Date>2019-03-06T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change><Change type="updated"><Date>2019-06-11T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-06-11T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="90276"><TitleDisplay>Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers</TitleDisplay><TitleOfficial>Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers, Two Batches of Symbicort Turbuhaler and Budesonide/Formoterol Easyhaler: Randomized, Double-blind, Double-dummy, Single-center, Single-dose, Crossover Study in Healthy Subjects</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">3103012</Identifier><Identifier type="NCT">NCT01668121</Identifier><Identifier type="Trial Acronym">REFLI</Identifier></Identifiers><Indications><Indication id="1185">Chronic obstructive pulmonary disease</Indication><Indication id="31">Asthma</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>budesonide + formoterol (Easyhaler)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>budesonide + formoterol fumarate, AstraZeneca</Name><Drug id="30712">budesonide + formoterol fumarate, AstraZeneca</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="30712">budesonide + formoterol fumarate, AstraZeneca</Drug><IndicationsPioneer/><Companies><Company><Company id="18693">Orion Corp</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="18693" type="Company"><TargetEntity id="4295866566" type="organizationId">Orion Oyj</TargetEntity></SourceEntity><SourceEntity id="1185" type="ciIndication"><TargetEntity id="10009033" type="MEDDRA"/><TargetEntity id="D029424" type="MeSH"/><TargetEntity id="-459670493" type="omicsDisease"/><TargetEntity id="277" type="siCondition"/></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"/><TargetEntity id="493" type="ICD9"/><TargetEntity id="10003553" type="MEDDRA"/><TargetEntity id="D001249" type="MeSH"/><TargetEntity id="-1473716268" type="omicsDisease"/><TargetEntity id="270" type="siCondition"/></SourceEntity><SourceEntity id="40" type="Action"><TargetEntity id="60" type="Mechanism">beta2-Adrenoceptor Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="18693">Orion Corp</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="40">Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2954">Steroidal anti-inflammatory</Class><Class id="3189">Corticosteroid agonist</Class><Class id="646">Bronchodilator</Class></Class><Technologies><Technology id="617">Aerosol formulation inhalant</Technology><Technology id="175">Drug combination</Technology><Technology id="616">Inhalant formulation</Technology><Technology id="753">Microparticle formulation</Technology><Technology id="618">Powder formulation inhalant</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="90">Steroid</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Bioequivalence</Term><Term>Pharmacokinetics</Term></TermsEndpoint><PatientCountEnrollment>48</PatientCountEnrollment><DateStart>2012-08-31T00:00:00Z</DateStart><DateEnd type="actual">2012-11-30T00:00:00Z</DateEnd><DateChangeLast>2018-05-12T04:42:42Z</DateChangeLast><DateAdded>2012-08-27T14:30:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Parexel International GmbH</Affiliation><Name>Rainard Fuhr, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Orion Corporation, Orion Pharma</Affiliation><Name>Merja MÃ¤kitalo</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Written informed consent (IC) obtained&lt;/li&gt;&lt;li&gt;Males and females, 18 to 55 (inclusive) years of age&lt;/li&gt;&lt;li&gt;Normal weight defined as body mass index (BMI)&amp;gt; 19 and &amp;lt; 30 kg/m2 (BMI =             weight/height[2])&lt;/li&gt;&lt;li&gt;Weight at least 50 kg&lt;/li&gt;&lt;li&gt;Forced expiratory volume in 1 s (FEV1) at least 80% of the predicted value             measured at the screening&lt;/li&gt;&lt;li&gt;Good general health ascertained by detailed medical history, and laboratory and             physical examinations&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Vulnerable subjects (ie, persons under any administrative or legal supervision)&lt;/li&gt;&lt;li&gt;Evidence of a clinically significant cardiovascular, renal, hepatic, hematological,             gastrointestinal, pulmonary, metabolic-endocrine, neurological or psychiatric disease             within previous two years; or evidence of active or quiescent pulmonary tuberculosis,             fungal and viral infections in the airways&lt;/li&gt;&lt;li&gt;Any condition requiring regular concomitant treatment (including vitamins and herbal             products) or likely to need any concomitant treatment during the study. As an             exception, paracetamol and ibuprofen for occasional pain are allowed&lt;/li&gt;&lt;li&gt;Intake of any medication that could affect the outcome of the study. As an exception,             contraceptives and hormone replacement therapy are allowed. The use of medicines             which are strong CYP3A4 inducers or inhibitors are restricted for at least 2 weeks             prior to the first study treatment administration and during the study&lt;/li&gt;&lt;li&gt;Any clinically significant abnormal laboratory value or physical finding (including             electrocardiogram [ECG] and vital signs) that may interfere with the interpretation             of test results or cause a health risk for the subject if he/she participates in the             study, as judged by the investigator. More specifically, supine HR &amp;lt; 45 or &amp;gt; 100 beats/min             after 10 min rest or supine systolic blood pressure (BP) &amp;gt; 140 or &amp;lt; 90 or diastolic BP &amp;gt; 90 or &amp;lt; 60             mmHg after a 10 min rest, or a QTc-Bazett (QTcB interval) &amp;gt; 450 ms at screening             evaluation&lt;/li&gt;&lt;li&gt;Known hypersensitivity to the active substances or the excipient (lactose, which             contains small amounts of milk protein) of the drug&lt;/li&gt;&lt;li&gt;History of vasovagal collapses&lt;/li&gt;&lt;li&gt;History of anaphylactic/anaphylactoid reactions&lt;/li&gt;&lt;li&gt;History of seizures including febrile seizures&lt;/li&gt;&lt;li&gt;Pregnant or lactating females&lt;/li&gt;&lt;li&gt;Females of child-bearing potential if they are not using proper contraception             (mechanical and/or hormonal contraception, intrauterine device [IUD] or surgical             sterilization). Double method of contraception is needed when using oral or             mechanical contraception: eg, condom in conjunct with oral contraception and             spermicidal product with mechanical contraception&lt;/li&gt;&lt;li&gt;Recent or current (suspected) drug abuse or positive result in the drugs abuse test&lt;/li&gt;&lt;li&gt;Recent or current alcohol abuse (regular drinking &gt; 21 units/week for             males and &gt; 16 units/week for females [1 unit = 4 cl spirits or             equivalent])&lt;/li&gt;&lt;li&gt;Current use of nicotine containing products more than five cigarettes (or             equivalent)/day and/or inability to refrain from the use of nicotine containing             products during the study (from the screening visit to the end-of-study visit)&lt;/li&gt;&lt;li&gt;Use of caffeine containing beverages &gt; 600 mg of caffeine/day and/or             inability to refrain from the use of caffeine containing beverages during the             treatment periods until 24 h after study treatment administration&lt;/li&gt;&lt;li&gt;Blood donation or loss of significant amount of blood within 30 days prior to the             first study treatment administration&lt;/li&gt;&lt;li&gt;Administration of another investigational drug within 30 days prior to the first             study treatment administration&lt;/li&gt;&lt;li&gt;Unsuitable veins for repeated venepuncture or for cannulation&lt;/li&gt;&lt;li&gt;Inability to learn the correct inhalation technique&lt;/li&gt;&lt;li&gt;Predictable poor compliance or inability to communicate well with the study centre             personnel&lt;/li&gt;&lt;li&gt;Inability to participate in all treatment periods&lt;/li&gt;&lt;li&gt;The subject is not able to understand and comply with protocol requirements,             instructions and protocol-stated restrictions&lt;/li&gt;&lt;li&gt;Positive result in HIV, hepatitis B or C tests&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Pharmacokinetic parameter Cmax of plasma budesonide concentration</Description><Timeframe>Within 12 h</Timeframe></Measure><Measure><Description>Pharmacokinetic parameter AUCt of plasma budesonide concentration</Description><Timeframe>Within 12 h</Timeframe></Measure><Measure><Description>Pharmacokinetic parameter Cmax of plasma formoterol concentration</Description><Timeframe>Within 24 h</Timeframe></Measure><Measure><Description>Pharmacokinetic parameter AUCt of plasma formoterol concentration</Description><Timeframe>Within 24 h</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The primary objective of this study was to evaluate the acceptance range with which two      &lt;ulink linkType="Drug" linkID="30712"&gt;Symbicort&lt;/ulink&gt; batches could be declared bioequivalent in a bioequivalence setting.&lt;br/&gt;The secondary objective was to compare pharmacokinetic parameters of the reference product      batches and budesonide/formoterol (Easyhaler).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;There were two arms in this study.&lt;br/&gt;Arm 1: subjects would receive &lt;ulink linkType="Drug" linkID="30712"&gt;Symbicort&lt;/ulink&gt;.&lt;br/&gt;Arm 2: subjects would receive  budesonide/formoterol.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Germany"><Sites><Site><Name>PAREXEL International GmbH</Name><Address1>Berlin</Address1><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01668121</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Asthma" id="6048"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Asthma" id="2773"><Criterion>Subjects with FEV1 Measurement</Criterion><SubCriteria><SubCriterion disease="Asthma" id="2779">Subjects with FEV1 &gt;=80% predicted</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Asthma" id="20240"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Asthma" id="20242"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Asthma" id="20245"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Asthma" id="20247"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Asthma" id="20252"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion><SubCriteria><SubCriterion disease="Asthma" id="20253">Subjects with contraindication to drugs or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Asthma" id="20255"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion><Exclusion disease="Asthma" id="25070"><Criterion>Subjects with specific cigarette smoking activity</Criterion><SubCriteria><SubCriterion disease="Asthma" id="3954">Smokers</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2012-11-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="estimated">2012-11-26T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>2.87 Months</EnrollmentPeriod><EnrollmentRate>16.72 Patients/Month</EnrollmentRate><DateFirstReceived>2012-08-15T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-08-27T14:30:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="9093"><TitleDisplay>Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery</TitleDisplay><TitleOfficial>A Multi-Center, Open-Label, Randomized Study of the Pharmacokinetics of Azithromycin Versus Moxifloxacin in Conjunctiva and Aqueous Humor Following Single or Multiple Ocular Administration of AzaSite Ophthalmic Solution, 1% or Vigamox in Subjects Undergoing Routine Cataract Surgery</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">041-103</Identifier><Identifier type="NCT">NCT00575380</Identifier><Identifier type="Secondary Organisational">P08655</Identifier></Identifiers><Indications/><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>azithromycin (ophthalmic sustained release, DuraSite), InSite</Name><Drug id="31495">azithromycin (ophthalmic sustained release, DuraSite), InSite</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>moxifloxacin (ophthalmic), Alcon</Name><Drug id="48941">moxifloxacin (ophthalmic), Alcon</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="31495">azithromycin (ophthalmic sustained release, DuraSite), InSite</Drug><IndicationsPioneer/><Companies><Company><Company id="18077">Merck &amp; Co Inc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="31495" type="Drug"><TargetEntity id="298817" type="siDrug">ISV-405</TargetEntity></SourceEntity><SourceEntity id="18077" type="Company"><TargetEntity id="4295904886" type="organizationId">Merck &amp; Co Inc</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>13</NumberOfSites><CompaniesSponsor><Company id="18077">Merck &amp; Co Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="15130">Ophthalmological antibacterial</Class><Class id="1538">Bacterial protein synthesis inhibitor</Class><Class id="1540">Macrolide antibiotic</Class><Class id="1594">Antibacterial</Class><Class id="463">Ribosome binding agent</Class></Class><Technologies><Technology id="66">Antibiotic</Technology><Technology id="620">Ophthalmic formulation</Technology><Technology id="659">Ophthalmic liquid formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="589">Sustained release formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Pharmacokinetics</Term></TermsEndpoint><PatientCountEnrollment>116</PatientCountEnrollment><DateStart>2007-12-31T00:00:00Z</DateStart><DateChangeLast>2018-07-14T09:53:35Z</DateChangeLast><DateAdded>2008-03-31T14:03:09Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Merck</Affiliation><Name>Reza Haque, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Participants scheduled to undergo routine cataract surgery by the investigator's preferred        technique&lt;/li&gt;&lt;li&gt;Have normal appearing, freely mobile, conjunctiva in the inferior temporal portion        cul-de-sac site of the operative eye&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Have concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either        eye&lt;/li&gt;&lt;li&gt;Have a history of ocular pemphigoid&lt;/li&gt;&lt;li&gt;Have ever had penetrating ocular surface surgery&lt;/li&gt;&lt;li&gt;Have had intraocular surgery within the past 3 months&lt;/li&gt;&lt;li&gt;Have ever had prior surgery or full penetrating trauma to the conjunctiva at the proposed        surgical site&lt;/li&gt;&lt;li&gt;Have a planned cataract surgery in the contraleteral eye within 2 weeks of the study        related surgical procedure and sample collection&lt;/li&gt;&lt;li&gt;Have a combined procedure planned (trabeculectomy surgery planned in the same eye as        cataract extraction surgery)&lt;/li&gt;&lt;li&gt;Have at the proposed conjunctiva biopsy site, signs of conjunctival shortening of the        fornix, scarring or adherence to the underlying episclera&lt;/li&gt;&lt;li&gt;Have according to the investigator's judgment, risk of intra or post-operative        complications related to their cataract surgery as a consequence of participation in the        study        &lt;/li&gt;&lt;li&gt;Have a known hypersensitivity to&lt;ulink linkType="Drug" linkID="31495"&gt;azithromycin&lt;/ulink&gt;, or any macrolide antibiotic or to any of the        ingredients in &lt;ulink linkType="Drug" linkID="31495"&gt;AzaSite&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Have had a known hypersensitivity to&lt;ulink linkType="Drug" linkID="48941"&gt;vigamox&lt;/ulink&gt; or any fluoroquinolone antibiotics or to any        of the ingredients in &lt;ulink linkType="Drug" linkID="48941"&gt;vigamox&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Are unable or unwilling to withhold for a minimum of 3 weeks prior to initiation of study        drug, the ocular or systemic use of either&lt;ulink linkType="Drug" linkID="31495"&gt;azithromycin&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="48941"&gt;moxifloxacin&lt;/ulink&gt;, when it is the        same medication as the subject's assigned study drug,  this relates as well, to the use of        either of these medications as a pre-surgical prophylaxis        &lt;/li&gt;&lt;li&gt;Are unable or unwilling to withhold for a minimum of 3 weeks prior to initiation of study        drug, the use of erythromycin ointment or ofloxacin&lt;/li&gt;&lt;li&gt;Have any ocular pathology with the exception of cataracts that in the judgment of the        investigator could confound study assessments or limit compliance&lt;/li&gt;&lt;li&gt;Have a serious systemic disease or uncontrolled medical condition or psychiatric condition        that in the judgement of the investigator could confound study assessments or limit        compliance&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Conjunctiva Concentration Prior to Cataract Surgery at One of Ten Time Points Ranging From 1 to 14 Days (Per Protocol Pharmacokinetic Population)</Description><Timeframe>Az(h): 1,12,48,49,72,144,145,168,216,312; Vig(h): 1,8,48,49,56,144,145,168,216,312</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Aqueous Humor Concentration Prior to Cataract Surgery at One of Ten Time Points Ranging From 1 to 14 Days (Per Protocol Pharmacokinetic Population)</Description><Timeframe>Az(h): 1,12,48,49,72,144,145,168,216,312; Vig(h): 1,8,48,49,56,144,145,168,216,312</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the study was to evaluate the drug concentrations in the conjunctiva and      aqueous humor of &lt;ulink linkType="Drug" linkID="31495"&gt;AzaSite&lt;/ulink&gt; (azithromycin) compared to &lt;ulink linkType="Drug" linkID="48941"&gt;Vigamox&lt;/ulink&gt;  (moxifloxacin) in subjects undergoing routine cataract      surgery.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects received &lt;ulink linkType="Drug" linkID="31495"&gt;AzaSite&lt;/ulink&gt; (one drop tid for 2 days and qd for the next 5 days) or &lt;ulink linkType="Drug" linkID="48941"&gt;Vigamox&lt;/ulink&gt; (one drop tid for 7 days). &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Cornea Consultants of Arizone</Name><Address1>Phoenix</Address1><Address2>Arizona</Address2><Address3>85032</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site><Site><Name>Eye Care Arkansas</Name><Address1>Little Rock</Address1><Address2>Arkansas</Address2><Address3>72205</Address3><CountrySubDivision code="AR">Arkansas</CountrySubDivision><Contacts/></Site><Site><Name>North Valley Eye Medical Group</Name><Address1>Mission Hills</Address1><Address2>California</Address2><Address3>91345</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Eye Center of North Florida</Name><Address1>Panama City</Address1><Address2>Florida</Address2><Address3>32405</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Center for Excellence in Eye Care</Name><Address1>Miami</Address1><Address2>Florida</Address2><Address3>33176</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Coastal Research Associates, LLC</Name><Address1>Atlanta</Address1><Address2>Georgia</Address2><Address3>30339</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts/></Site><Site><Name>Kentuckiana Institute for Eye Research</Name><Address1>Louisville</Address1><Address2>Kentucky</Address2><Address3>40207</Address3><CountrySubDivision code="KY">Kentucky</CountrySubDivision><Contacts/></Site><Site><Name>Ophthalmology Associates</Name><Address1>St. Louis</Address1><Address2>Missouri</Address2><Address3>63131</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts/></Site><Site><Name>Ophthalmic Consultants of Long Island</Name><Address1>Rockville Centre</Address1><Address2>New York</Address2><Address3>11563</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>Eye Care Specialists</Name><Address1>Kingston</Address1><Address2>Pennsylvania</Address2><Address3>18704</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts/></Site><Site><Name>Glaucoma Consultants and Center for Eye Research</Name><Address1>Mount Pleasant</Address1><Address2>South Carolina</Address2><Address3>29464</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Medical University of South Carolina</Name><Address1>Charleston</Address1><Address2>South Carolina</Address2><Address3>29464</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Corona Research Consultants</Name><Address1>El Paso</Address1><Address2>Texas</Address2><Address3>79904</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Cataract</Disease><PatientSegments><PatientSegment><PatientSegment id="11763">Subjects with History/Scheduled for Cataract Extraction</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Bacterial Conjunctivitis</Disease><PatientSegments><PatientSegment><PatientSegment id="11450">Subjects at risk of developing disease</PatientSegment><SubSegments><SubSegment id="11451">Subjects with history/scheduled for ophthalmic surgery</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00575380</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Bacterial Conjunctivitis" id="17896"><Criterion>Subjects at Risk of Developing Disease</Criterion><SubCriteria><SubCriterion disease="Bacterial Conjunctivitis" id="17897">Subjects with history/scheduled for ophthalmic surgery as a risk factor</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cataract" id="21924"><Criterion>Subjects with History/Scheduled for Cataract Extraction</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Bacterial Conjunctivitis" id="15677"><Criterion>Subjects with Conjunctivitis</Criterion><SubCriteria><SubCriterion disease="Bacterial Conjunctivitis" id="15680">Subjects with other types of conjunctivitis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Bacterial Conjunctivitis" id="15682"><Criterion>Subjects co-morbid with Ocular Disorders/Diseases</Criterion></Exclusion><Exclusion disease="Bacterial Conjunctivitis" id="15684"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Bacterial Conjunctivitis" id="15685"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Bacterial Conjunctivitis" id="15686"><Criterion>Subjects on Antibiotic Medications</Criterion></Exclusion><Exclusion disease="Bacterial Conjunctivitis" id="15691"><Criterion>Subjects with History/Scheduled for Ophthalmic Surgery</Criterion></Exclusion><Exclusion disease="Cataract" id="19815"><Criterion>Subjects co-morbid with Ocular Disorders/Diseases</Criterion><SubCriteria><SubCriterion disease="Cataract" id="19818">Subjects with ocular inflammatory/infectious disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cataract" id="19831"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Cataract" id="19832"><Criterion>Subjects with History of/Scheduled for Ocular Therapy</Criterion><SubCriteria><SubCriterion disease="Cataract" id="19834">Subjects with history of/scheduled for ocular procedures</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cataract" id="19836"><Criterion>Subjects with Surgery Complications</Criterion></Exclusion><Exclusion disease="Cataract" id="19839"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion><SubCriteria><SubCriterion disease="Cataract" id="19840">Subjects with contraindication to drugs or its excipients</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2008-06-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2008-03-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>3.03 Months</EnrollmentPeriod><EnrollmentRate>38.28 Patients/Month</EnrollmentRate><DateFirstReceived>2007-12-12T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-03-31T14:03:09Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial></trialRecordsOutput>